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ABSTRACT
IFNAR1 SIGNALING NEGATIVE REGULATES
MYELOID-DERIVED SUPPRESSOR CELLS IN CANCER
Kevin M. Alicea-Torres
Dmitry I. Gabrilovich
Myeloid-derived

suppressor

cells

(MDSC)

are

pathologically

activated

neutrophils and monocytes with potent immune suppressive activity. These cells play an
important role in tumor progression and limit the efficacy of cancer therapies. Whereas
many pathways stimulate the generation of MDSC, the key natural mechanisms
restricting these processes are not well understood. Here, we present evidence that type I
interferons (IFN1) receptor signaling in neutrophils and monocytes serves as a universal
mechanism that restrict acquisition of suppressive activity by these cells. Downregulation
of the IFNAR1 receptor and inactivation of the IFN1 pathway was found in MDSC from
cancer patients and several mouse tumor models. The decrease in IFNAR1 depended on
the activation of the p38 kinase and was required for activation of the immune
suppressive phenotype. Genetic manipulation of IFNAR1 that prevents its degradation
and retains signaling, completely abrogated generation of MDSC in tumor-bearing mice
and had potent antitumor effect. Deletion of IFNAR1 was not sufficient to convert
neutrophils and monocytes to MDSC. Stabilizing IFNAR1 using p38 inhibitor combined
with the interferon induction therapy using Poly:IC elicited a robust anti-tumor effect.
Thus, negative regulatory mechanisms of MDSC function can be exploited
therapeutically.
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CHAPTER ONE: MYELOID-DERIVED SUPPRESSOR CELLS
Reprinted by permission from Springer Nature Customer Service Centre GmbH: Springer
Nature. Alicea-Torres K., Gabrilovich D.I. (2018) Biology of Myeloid-Derived
Suppressor Cells. In: Zitvogel L., Kroemer G. (eds) Oncoimmunology. Springer,
Cham. https://doi.org/10.1007/978-3-319-62431-0_10

Introduction
Tumor progression is associated with the altered myelopoiesis. Myeloid-derived
suppressor cells (MDSC) are now established as a critical factor that modulates immune
responses in cancer. MDSCs represent an expanded heterogeneous group of immature
myeloid cells that are associated with poor prognosis and survival of cancer patients

1,2

.

MDSC are characterized by potent immune suppressive activity, which contribute to
tumor growth and progression. In addition, MDSCs are also implicated in the promotion
of angiogenesis and metastasis

3,4

. It is clear that MDSCs have many roles in cancer,

however, immunosuppression of T cell responses within the tumor microenvironment is
their hallmark and the focus of many studies 5. Therefore, by understanding the biology
of MDSCs, therapeutic strategies can be developed in hopes of targeting these cells in
cancer patients.

Characterization of MDSCs in Mouse and Humans
MDSCs were initially characterized and described in tumor-bearing mice as
heterogeneous cells of myeloid origin that express both myeloid lineage differentiation
markers, Gr-1 (glutathione reductase) and CD11b (αM integrin) markers 6. MDSCs
subsets have been identified based in the intensity of GR1 expression (GR1low, GR1int,
and GR1bright) with other phenotypic markers, such as F4/80 (marker for macrophages) or
1

MHCII (major histocompatibility complex class II) 7. However, GR1 consists of two
epitopes, Ly6C and Ly6G, which can be detected by different antibodies. This led to the
identification of two different MDSCs subsets: granulocytic or polymorphonuclear (G- or
PMN-MDSCs, CD11b+Ly6G+Ly6Clow) and monocytic (M-MDSC, CD11b+Ly6GLy6Chigh) cells; these cells are morphologically and phenotypically similar to neutrophils
and monocytes, respectively

8

(Figure 1.1). In the majority of cancer types, PMN-

MDSCs are the most abundant population representing more than 70% of all MDSCs,
whereas M-MDSCs represent the majority of the remaining cells 9. In addition, within
these MDSCs subsets, there is a small population representing less than 5% that consists
of a mixture of progenitors and precursors that are currently under investigation. Murine
MDSCs are generated in the bone marrow upon exposure to tumor-derived factors and
predominantly accumulate in the peripheral blood, spleen, liver, lungs, and tumor.

Figure 1.1. Origin of MDSCs. In the bone marrow, hematopoietic stem cells (HSC)
differentiate into common myeloid progenitor (CMP) followed by granulocytemacrophage progenitor (GMP), which give rise to immature myeloid cells mainly
comprised of precursors of neutrophils and monocytes. In normal condition, immature
myeloid cells differentiate into macrophages, dendritic cells and neutrophils (black
arrows). However, during cancer progression the tumor microenvironment produce and
2

secrete growth factors, cytokines and chemokines that altered the myelopoiesis in the
bone marrow. These tumor-derived factors block the differentiation of immature myeloid
cell to fully mature cells creating an accumulation of pathological activated immature
monocytes and neutrophils known as M-MDSCs and PMN-MDSCs, respectively (red
arrows). Besides the expansion of MDSCs during tumor progressions, these cells acquire
potent immunosuppressive activity. Within the tumor microenvironment, M-MDSCs
differentiate to TAMs with similar ability to suppress anti-tumor immune responses.
In humans, MDSCs have been identified and studied primarily in the peripheral
blood mononuclear cell (PBMCs) fraction. However, humans do not have Gr-1 antigens,
which make direct comparison between mice and human MDSCs difficult. PMN-MDSCs
are defined as CD11b+CD14-CD15+ or CD11b+CD14-CD66b+ whereas M-MDSCs are
defined as CD11b+CD14+HLA-DR-/loCD15- 10. There is a small population that include a
mixed group of MDSCs characterized as Lin- (including CD3, CD14, CD15, CD19 and
CD56) HLA-DR-CD33+ cells. This population that comprised a more immature
phenotype have been defined as “early-stage MDSCs (e-MDSCs). At the moment, the
minimum requirement to define and characterize human MDSCs, including PMNMDSCs, M-MDSCs and e-MDSCs, should follow the phenotypic criteria 10. Using these
criteria, M-MDSCs are separated from monocytes based on the expression of HLA-DR
(MHC class II molecule). On the other hand, the only method to separate PMN-MDSCs
from normal neutrophils is by gradient centrifugation using a standard Ficoll gradient.
PMN-MDSCs are found enriched in the low-density fraction (PBMCs) whereas
neutrophils are found within the high-density fraction 11,12. Recently, lectin type oxidized
LDL receptor 1 (LOX1) has been identified as a potential marker of PMN-MDSCs in
humans

12

. LOX-1 expression on neutrophils could be used for direct identification of

PMN-MDSCs found in blood and tumor tissue. Furthermore, LOX-1+ neutrophils
3

isolated from the blood of cancer patients were shown to suppress T cell proliferation
whereas LOX-1- neutrophils were not suppressive.

Mechanism of MDSC-Mediated Immune Suppression
To fully identify myeloid cells as MDSCs, their functional activity needs to be
tested; this is achieved usually by an in vitro suppression assay, which measures their
ability to suppress the function of immune cells in tumor-bearing hosts. Activated
MDSCs are implicated in the direct suppression of NK and B cells along with their
primary target, T cells

13,14,15

. Immune suppression by MDSCs involves several

mechanisms such as the increase of arginase 1 (Arg1) and inducible nitric oxide
synthases (iNOS) production, the increased production of reactive oxygen and nitrogen
species (ROS and peroxynitrite, PNT) and other immune suppressive factors.
Upregulation of Arg1 in MDSCs leads to the depletion and conversion of L-arginine, an
essential amino acid needed for T cell proliferation, to urea and L-ornithine

16

. Under

limiting amounts of L-arginine, upregulation of iNOS in MDSCs leads to the production
of nitric oxide (NO) which reacts with superoxide and generates PNT

17

. Production of

PNT by MDSCs causes the nitration and nitrosylation of the T cell receptor (TCR) thus
disrupting potential CD8+ T cell – antigen interactions leading to T cell tolerance 18. Also,
PNT reduces the binding of antigenic peptides to MHC molecules on tumor cells and
blocks T-cell migration by nitrating T-cell-specific chemokines, such as CCL2.

19,20

Another mechanism for suppression of T cell responses is the production of ROS by
MDSCs. It has been shown that tumor-derived factors generate MDSCs that produced
high levels of ROS which contribute to the suppressive activity of these cells. 21 Although
4

these are the major mechanisms of immunosuppression by MDSCs, there are several
other factors involved including transforming growth factor β (TGFβ), interlukin 10 (IL10), cyclooxygenase-2 (COX-2), indoleamine 2,3-dioxygenase (IDO), and many others.
The main immunosuppressive cytokines produced by MDSCs are TGFβ and IL-10.
Although TGFβ has shown to be produced by tumor cells, the production of this cytokine
by MDSCs inhibit cytotoxic T cell responses in tumor-bearing mice. 22 MDSCs produced
high amounts of IL-10 which impairs anti-tumor responses by inhibiting T cell activation.
23

In addition, MDSCs expressed several enzymes that are involved in the depletion of

essential nutrition factors for T cell function. Upon stimulation by pro-inflammatory
molecules, COX-2 is activated and induces Arg1 activity in MDSCs. 16 Other studies had
implicated IDO expression in MDSCs which inhibit T cell function by depleting Ltryptophan and inducing T cell apoptosis within the tumor microenvironment. 24 MDSCs
also block T cell function by depleting cysteine and impairing T cell activation in tumor.
25

In addition, MDSCs have the ability to induce the expansion of regulatory T cells

(Treg).

26,27

Most of the mechanisms of suppression found to be implicated in MDSC

function do not act simultaneously and are dependent on type of MDSC, type of tumors,
and location of the cells.
Several recent studies have provided evidence that the ratio of PMN-MDSCs-toM-MDSCs is really important because these cells utilize different mechanisms to
suppress T cell responses.

28

For instance, M-MDSCs have the ability to suppress T cell

activation in an antigen-specific and non-specific manner. This suppression of T cell
responses by M-MDSCs is associated with the increased expression of iNOS and
5

28,29

production of NO.

On the other hand, PMN-MDSCs are capable of suppressing

immune responses primarily in an antigen-specific manner, which induces CD8+ T cell
tolerance in the host. Immune suppression by PMN-MDSCs is associated with the
increased expression of Arg1 along with high levels of ROS and PNT.

8,18

Although

PMN-MDSCs are more abundant than M-MDSCs in a tumor-bearing host, they are less
immunosuppressive than M-MDSCs when compared on a per cell basis. 30 Location was
also determine to be important in dictating the strength of suppression by MDSCs. Recent
years have provided ample evidence indicating that MDSCs in the tumor
microenvironment are more suppressive than MDSCs in peripheral lymphoid organs and
peripheral blood.

31,32

There is clear evidence now suggesting that the increased

suppressive activity of MDSCs is regulated by the low levels of oxygen (hypoxia) found
in tumor tissues.

33

However, more studies are needed to better understand what other

tumor-associated factors and mechanisms are implicated in the potent suppressive
activity by MDSCs within the tumor microenvironment (Figure 1.2).

6

Figure 1.2. Mechanisms of immunosuppression by MDSCs in cancer. In cancer, both
M-MDSCs and PMN-MDSCs can suppress antitumor T cells responses through different
mechanisms. During tumor progression, these mechanisms are regulated by several
transcription factors and enzymes, and by the activation of the ER stress response. a) In
hypoxia conditions, upregulation of HIF-1α induces the differentiation of M-MDSCs into
TAMs in a STAT3-dependent manner. In the tumor microenvironment, TAMs suppress
T cells responses by sequestering arginine through activation of Arg1. b) M-MDSCs
deprive T and B cells of essential amino acids including arginine and cysteine. c) The
main mechanism of immunosuppression by M-MDSCs, is the expression of iNOS and
release of NO. The release of NO causes the nitration or nitrosylation of T cell receptors
as wells as chemokines that attract T cells. d) Both M-MDSCs and PMN-MDSCs release
IL-10 and TGFβ which induces the development and expansion of antigen-specific Tregs,
that may require CD40-CD40L interactions. Furthermore, the release of TGFβ is
implicated in the suppression of NK cells by MDSCs. Within the tumor
microenvironment, MDSCs subsets upregulate PDL-1 expression which interact with
PD-1 on T cells resulting in cell death. e) Similarly to M-MDSCs, PMN-MDSCs
suppress T cell responses by depleting arginine and cysteine from the tumor
microenvironment. f-g) PMN-MDSCs are characterized by their release of reactive
nitrogen or oxygen species. f) The production of peroxinitrite by PMN-MDSCs causes
the nitration or nitrosylation of the TCR chain inhibiting T cell proliferation. Another
important function of peroxynitrite release by MDSCs, is the modification of CCL2,
chemoattractant, which affect T cell migration. g) Also, activation of NOX is responsible
for the increased production of reactive oxygen species by tumor-associated PMNMDSCs.

Mechanisms Regulating MDSC Accumulation and Function
One of the main questions in the MDSC field is how is their expansion,
accumulation and activation regulated? Several years ago, we proposed a two-signal
model describing that MDSC accumulation requires two distinct types of signals 34. This
model is divided in two phases: 1) the expansion phase associated with the inhibition of
their terminal differentiation and 2) the activation phase that is responsible in the
conversion of immature myeloid cells into immunosuppressive MDSCs. However, we
assert that these two phases partially overlap but are governed by different sets of
transcription factors and intermediates (Figure 1.3).

7

Figure 1.3. Tumor associated factors and molecular pathways regulating MDSCs
expansion and function in cancer. The tumor microenvironment produced a large
number of cytokines and immune suppressive mediators that regulate MDSCs expansion
and immune suppressive activity, signal 1 and 2, respectively. Exposure of MDSCs with
to tumor-secreted growth factors (Signal 1) and other mediators, regulate several
signaling pathways involved, especially STAT3, in M-MDSCs or PMN-MDSCs
expansion and accumulation. However, for the acquisition of immune suppressive
activity by immature myeloid cells an activation signal (Signal 2) is required giving rise
to both M-MDSCs and PMN-MDSCs. These signaling pathways are important for both
PMN-MDSCs and M-MDSCs (NF-kB, STAT3, STAT6, ER stress response) and others
may have opposite roles in MDSCs subsets (STAT1). COX-2 has been described to be
more specific to M-MDSCs.
The first phase is mostly driven by tumor-derived growth factors along with
STAT3, IRF8, C/EBPβ, RB1, Notch, adenosine receptors A2b and NLRP3.
STAT3 – Activation of signal transducer and transcription activator 3 (STAT3) in
MDSCs requires myeloid-specific growth factors such as GM-CSF, G-CSF, M-CSD, IL6, VEGF and several other factors

35

. STAT3 plays a major role in the regulation of

MDSCs. For example, tumor-bearing mice treated with different STAT3 inhibitors have
8

shown a decrease in MDSCs accumulation 36. Interestingly, STAT3 is not only involved
in the expansion of MDSCs, but also in their function and differentiation; for instance,
M-MDSCs are able to differentiate into tumor-associated macrophages (TAMs) within
the tumor microenvironment through STAT3 regulation

37,38

. IRF8 – IFN regulatory

factor 8 (IRF8) has been described as a negative regulator of MDSCs differentiation. In
the absence of IRF8, there is an increased in MDSCs accumulation in both spleen and
tumor tissue, however, overexpression of IRF8 resulted in a decreased accumulation of
MDSCs in a spontaneous mouse tumor model

39,40

. C/EBPβ – CAAT-enhancer-binding

protein beta (C/EBPβ) is the only member of its family that has been implicated in
MDSC expansion. Mice lacking C/EBPβ specifically in hematopoietic cells had lower
frequencies of MDSCs - especially M-MDSCs - suggesting its role in MDSCs
differentiation

41

. Rb1 – The retinoblastoma protein 1 (Rb1) has been implicated in

MDSCs found in both mice and humans

42

. In tumor-bearing mice, Rb1 was shown to

regulate the differentiation of M-MDSCs to PMN-MDSCs. M-MDSCs with high levels
of Rb1 mainly give rise to macrophages and DCs, whereas the vast majority of MMDSCs with low levels of Rb1 differentiate towards PMN-MDSCs. Recently, the
accumulation of Rb1lo Ly6G+ PMN-MDSC was confirmed in a transgenic model of
breast cancer in mice

43

. Notch Pathway – Another pathway involved in the

accumulation and differentiation of MDSCs is Notch signaling pathway. It has been
shown that notch is downregulated upon activation of casein kinase 2 (CKII) in MDSCs.
Therefore, tumor-bearing mice treated with CKII inhibitor showed an improvement in
notch signaling and DC differentiation

44

These results suggests that the downregulation
9

of notch signaling skewed the differentiation of the hematopoietic progenitors toward
MDSCs instead of DCs. Recently, it has been shown that the inhibition of notch signaling
enhances the generation of PMN-MDSCs but decreases the production of M-MDSCs 45.
Adenosine Receptor A2B – Another factor that regulates the accumulation of MDSCs is
adenosine. In the tumor microenvironment, there is an increased level of extracellular
adenosine that is associated with MDSC accumulation via engagement of the adenosine
receptor A2b expressed on MDSCs

46

. Tumor-bearing mice lacking A2b had lower

number of MDSCs compared to wild type, suggesting that the A2b receptor is critically
involved in the expansion of MDSCs, especially PMN-MDSCs.

47

This correlates with a

most recent study using a melanoma model treated with an agonist and an antagonist of
A2b, in which treatment with the agonist increased both tumor growth and MDSC
accumulation whereas treatment with the antagonist resulted in a decreased of tumor
progression with a reduction of MDSC numbers within tumor tissues.

48

NLRP3 – NLR

family, pyrin domain containing 3 (NLRP3) is an intracellular sensor associated with the
inflammasome, that upon activation, induces the generation of interleukin (IL)-1β and IL18. Tumor-associated MDSCs express NLRP3, and Nlrp3-/- mice had lower levels of
MDSCs within tumor tissues compared to wild-type mice, suggesting that NLRP3 may
play a role in the expansion and accumulation of MDSCs.

49

However, more studies are

needed to determine the exact role of NLRP3 in MDSC function. Clearly, these signaling
pathways regulate MDSC expansion and are involved in blocking normal immature
myeloid cell differentiation. However, the majority of these factors are implicated in the

10

first phase of MDSCs regulation but are not sufficient to promote their activation into
immunosuppressive cells.
As part of our two-signal model, the acquisition of the suppressive activity found
in MDSCs is mediated by factors mostly produced by the tumor stroma including proinflammatory molecules such as IFNγ, IL-1β, IL-13, toll-like receptor (TLR) ligands and
others. Each of these molecules are involved in the activation of several signaling
pathways associated with many factors such as NF-kB, STAT1, STAT6, prostaglandin E2
(PGE2) and cyclooxygenase (COX-2), high mobility group box 1 (HMGB1) and hypoxiainducible factor-1α (HIF-1α); all of which are implicated in the suppressive activity of
MDSCs. Recently, the endoplasmic reticulum (ER) stress pathway has been linked to the
suppressive activity of MDSCs found in cancer.
NF-kB – In MDSCs, the activation of the NF-kB pathway is predominately
mediated by the TLR ligands: IL-1β or TNF-α - both of which have been shown to
increase suppressive activity.

34

The role of TLR ligands in MDSC function is still not

clear. Some studies have shown that TLR ligands drive the suppressive activity of
MDSCs whereas others suggest that these ligands inhibit their function.

50,51,52

. During

inflammation and cancer, IL-1β produced by tumors cells leads to the activation of
MDSCs through the NF-kB pathway resulting in the increased production of PNT.
53,54,14,55

Another well-known activator of the NF-kB pathway is tumor necrosis factor-α

(TNF-α), which is implicated in the maturation and function of MDSCs 56. It was shown
that the transmembrane (tm) form of TNF-α could increase the suppressive activity of
MDSCs via its receptor and regulate iNOS expression in a NF-kB dependent manner.
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57

One study using an inflammatory mouse model showed that the role of TNF-α is
restricted to M-MDSCs.

58

Also, activation of NF-kB through TNF-α receptor could

promote survival of MDSCs.

59

At this moment, NF-kB can be involved in MDSCs

expansion, but its main role is to signal activation of these cells leading to acquisition of a
suppressive phenotype, especially in M-MDSCs. STAT1 – Several studies had shown
that activation of STAT1 is linked to the suppressive activity of MDSCs. 60,61,17 STAT1 is
activated upon IFNγ stimulation and is involved in the up-regulation of iNOS and Arg1
expression. Sinha et al. demonstrated that activation of STAT1 through IFNγ did not
regulate MDSC accumulation or function.

62

Subsequent studies focused on the role of

the IFNγ – STAT1 pathway in the suppressive activity of MDSC subsets. A recent study
showed that STAT1 plays a major role by increasing the suppressive function of MMDSCs.

63

However, activation of STAT1 through IFNγ receptors was shown to

decrease PMN-MDSCs function and survival.

64

These studies suggest that the IFNγ –

STAT1 signaling pathway may have opposite roles in M-MDSCs and PMN-MDSCs.
Indeed, this could explain why the initial study did not observe the involvement of IFNγ
and/or STAT1 in the suppressive activity of MDSCs since the study of Sinha et al.
analyzed the function of total MDSCs (CD11b+Gr-1+) rather than the subsets separately.
It is possible that high PMN-MDSCs numbers, and not M-MDSCs, compensate with the
suppressive activity observed in the absence of the STAT1 signaling pathway. STAT6 –
Another transcription factor involved in the function of MDSCs is STAT6. In MDSCS,
the STAT6 signaling pathway is activated upon stimulation with IL-4 and IL-13 through
its receptor (CD124, IL-4Rα) leading to the upregulation of Arg1 expression and
12

production of TGF-β, a potent inhibitor of T cell proliferation. 65,66,22 In addition, STAT6
has been shown to be involved in the survival and accumulation of MDSCs. 67 PGE2 and
COX-2 – Prostaglandins, especially PGE2, plays a major role in the suppressive activity
of MDSCs in cancer. Rodriguez and colleagues found that the signaling through the
PGE2 receptor E-prostanoid (EP) 4, which is expressed in MDSCs, induces Arg1
expression and its activity.

16

Furthermore, expression of the main regulator of PGE2

production, COX-2, was directly correlated with the induction of Arg1 and iNOS in
tumor-infiltrating MDSCs.

68

These results were confirmed by Obermajer et al. in which

they described a positive feedback loop between PGE2 and COX-2 that led to the
69

conversion of monocytes into M-MDSCs.

Based on this, ex vivo MDSCs were

generated using PGE2 which induce the production of suppressive factors.

70

In mouse

models of mesothelioma and glioma, treatment with a COX-2 inhibitor blocked the
accumulation and function of MDSCs.

71,72

Moreover, the involvement of PGE2 in

MDSC function, was confirmed in melanoma patients that were treated with a COX-2
inhibitor and had MDSC-like cells with less suppressive activity. 73 Primarily, PGE2 has
shown a role in the regulation of immune suppression by MDSCs but has been implicated
also in their recruitment and accumulation.

74

HGMB1 - HGMB1 is a DNA binding

protein that present at high levels within the tumor microenvironment. 75 HGMB1 affects
MDSC via binding to TLR4 and receptor for advanced glycation end products (RAGE).
Signaling through both receptors activate the NF-kB pathway. Parker et al. demonstrated
that HGMB1 drives the accumulation and suppressive activity of MDSCs and also
promotes the survival of MDSCs by inducing autophagy in cells within the tumor
13

microenvironment.

76

Recently, Su et al. demonstrated that in vivo HGMB1 blockade

with a monoclonal antibody against HGMB1 B box decreased the accumulation of MMDSCs in both spleen and tumor tissues. 77 These studies demonstrate that HGMB1 may
play a key role in the accumulation and function of MDSCs. HIF1α – The absence of
oxygen (hypoxia) is one of the biggest differences between the tumor microenvironment
and peripheral lymphoid organs. It has been shown that within the tumor
microenvironment and in response to hypoxia, HIF-1α can regulate MDSC function and
the differentiation of M-MDSCs to TAMs in a STAT3-dependent manner.

37,38

. More

recently, Norman et al. demonstrated that HIF-1α selectively upregulated programmed
death-ligand 1 (PD-L1), an immune checkpoint ligand on MDSCs. 78 (Figure 1.3).
Recent studies have suggested that ER stress responses are involved in the
suppressive behavior of MDSCs in tumor-bearing hosts. The ER stress response pathway,
also known as the unfolded protein response (UPR), is responsible for preserving ER
homeostasis during extrinsic or intrinsic stress.

79,80

ER stress response is comprised of

three ER-localized transmembrane protein sensors: inositol-requiring enzyme 1α
(IRE1α), activating transcription factor 6α (ATF6α) and double-stranded RNA-dependent
kinase (PKR)-like ER related kinase (PERK). Activation of these ER sensors leads to the
upregulation of several transcription factors including the spliced X box protein 1
(sXBP1), CCAAT-enhancer-binding protein homologous protein (CHOP) and others.
Both MDSCs isolated from tumor-bearing mice and cancer patients overexpress several
markers of ER stress, including sXBP1 and CHOP, and display an enlarged ER - a
hallmark of ER stress.

81

Tumor-bearing mice treated with thapsigargin, an ER stress
14

inducer, have an increased number of MDSCs with potent suppressive activity.

82

We

showed that induction of ER stress with thapsigargin converts normal human neutrophils
to a suppressive PMN-MDSC phenotype in an IRE1α/XBP1-dependent manner.

12

Besides the role of IRE1α/XBP1 in MDSC function, recent findings have implicated
CHOP in the suppressive activity of tumor-associated MDSCs. For example, CHOPdeficient MDSCs lose their suppressive function and acquire an immune stimulatory
phenotype. 83,84 Although CHOP-deficient MDSCs did not have the ability to suppress T
cells that were stimulated in an antigen-nonspecific manner, they retained their ability to
block antigen-specific T cells.

85

At this moment, only the IRE1α/XBP1 and

PERK/CHOP signaling pathways have been implicated in the function of MDSCs.
However, more studies are needed to understand the specific mechanisms of ER stress
responses that regulate the suppressive activity of MDSCs.

Relationship of MDSCs with other Myeloid Cells
Over the years, our understanding of myeloid cells in cancer has shed light to
their important role in tumor development, progression and metastasis. The main three
groups of terminally differentiated myeloid cells are macrophages, DCs, and PMNs. It is
now clear that the tumor microenvironment alters myeloid cell differentiation by
arresting these cells in an immature stage with potent immunosuppressive activity.
Another myeloid cell involved in immune suppression is the tumor-associated
macrophage (TAM) that arises from a tumor-infiltrating monocyte or M-MDSC within
the tumor microenvironment. However, the relationship of MDSCs with other myeloid
cells is still not clear. The main concern is the lack of specific markers for MDSCs
making it difficult to discreetly identify these cells separate from monocytes and
15

neutrophils. This is why in many previous studies MDSC-like cells with suppressive
activity were called monocytes and neutrophils. Recent data has provided evidence about
the specific nature of MDSCs in cancer. 1) Immunosuppressive activity is an intrinsic
feature of MDSCs. For instance, MDSCs could be generated in vitro from bone marrow
progenitor cells in the presence of tumor-secreted factors. Unlike MDSCs, mature
neutrophils or monocytes in the presence of these tumor-associated factors cannot
suppress T cell responses in vitro. 2) Several studies, involving genomic, proteomic and
transcriptomic analysis, had provided evidence that supports the differences between
PMN-MDSCs and neutrophils in tumor-bearing mice.

86,87,88,89,90

Moreover, a recent

study provided information that suggests that PMN-MDSCs are different to neutrophils
from healthy donors or cancer patients based in their gene profile.

12

In humans, PMN-

MDSCs can be distinguished from neutrophils by LOX-1 expression. In mice the role of
LOX-1 is not clear. 3) Within the hypoxic tumor microenvironment, M-MDSCs
differentiate into TAMs and this is regulated by HIF-1α and STAT3 activation.

9,33,37,38,

Both myeloid cells have potent immune suppressive function, especially within the tumor
sites, however, M-MDSCs can be distinguished from TAMs by changes in
monocyte/macrophage-associated markers. The main changes observed during MMDSCs differentiation into TAMs includes an increased in F4/80 and CD115,
intermediate expression of Ly6C, and low expression of IRF8 and S100A9 protein.

91,92

4) MDSCs possess several biochemical features that are not observed in neutrophils or
monocytes including high Arg1 and iNOS expression and activity as well as high levels
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of ROS and PNT production. In addition, recent studies have shown that MDSCs have an
increase in the ER stress response that is linked to their suppressive function.
Among the different types of myeloid cells in cancer, there is a better understanding of
the relationship between M-MDSCs and TAMs. Recent data from several groups have
shown that M-MDSCs are TAM precursors within the tumor microenvironment. In
addition, there are two polarized phenotypes of macrophages: the classically activated
(M1 macrophages) with anti-tumor properties and the alternatively activated (M2
macrophages) with pro-tumor properties. The latter is more related to TAMs, but it is
unclear if these two phenotypes are that of the same macrophage and what the molecular
mechanism is that regulates them within the tumor microenvironment. 93 In addition, it is
unknown if the polarization of macrophages is dictated by M-MDSCs before TAM
differentiation. On the other hand, the nature of PMN-MDSCs and their relationship with
neutrophils is a subject of discussion in different studies and an ongoing debate. Although
PMN-MDSCs are widely accepted in the field, the concept of neutrophil polarization in
cancer raises questions of whether these cells are pathologically similar to PMN-MDSCs.
94

Similarly to macrophages, the concept of tumor-associated neutrophils (TANs) consist

of neutrophils with anti-tumor (N1 cells) or pro-tumor (N2 cells) properties within the
tumor microenvironment. 95 Studies have implicated TGF-β and type 1 interferons (IFNs)
as cytokines in the regulation of TANs plasticity in cancer

95,96,97

. Neutrophils by

definition are short-lived and terminally differentiated cells, whereas PMN-MDSCs are
immature cells. For this reason, is hard to imagine that TANs could be polarized in the
tumor microenvironment. Indeed, several studies have shown that these cells have the
17

ability to suppress T cell responses in tumor-bearing mice, which supports these cells as
PMN-MDSCs.

98,99

However, the anti-tumor role of TANs has been described in cancer

patients. Recently, Eruslanov et al. observed that TANs from early-stage lung cancer
patients were not immunosuppressive, but rather stimulate T cell responses. 100 This study
provides evidence for the role of TANs during early stages of tumor initiation. Only few
studies have addressed the role of MDSCs in tumor initiation and how it regulates the
immune responses at early stages. For instance, Ortiz et al. showed that the exposure of
mice to cigarette smoke resulted in an accumulation of non-suppressive MDSC-like cells
in various organs. 101 However, when cigarette smoke was combined with a carcinogen to
promote the development lung cancer, MDSCs presented potent immunosuppressive
activity. These data suggest that MDSC function is controlled by the tumor
microenvironment. Our understanding of the nature of MDSCs and their relationship
with other myeloid cells during tumor development would open new therapeutic
opportunities.

Therapeutic Strategies to Target MDSCs in Cancer
There is ample evidence that MDSC accumulation in peripheral lymphoid organs
and tumor tissues correlates with a poor prognosis and clinical outcome in cancer
patients.

102

In addition, MDSCs are implicated in resistance to anticancer therapies

including the receptor tyrosine kinase inhibitor sunitinib as well as several
chemotherapeutic drugs for lung cancer and multiple myeloma. 103,104,105 Since these cells
have the ability to suppress anti-tumor immune responses, the success of cancer
therapies, including immunotherapy, would depend on the immunosuppressive effect by
MDSCs. Indeed, several clinical studies had shown an association with MDSCs levels
18

and response to immune checkpoint inhibitors, ipilimumab (anti-CTLA-4) and nivolumab
(anti-PD-1).

106,107,108,109

Today, the increased knowledge of the molecular mechanisms

responsible for accumulation and function of MDSCs in cancer has allowed for the
development of therapeutic strategies targeting this cell population. Some strategies for
targeting MDSCs include a) elimination of MDSCs, b) blocking accumulation of MDSCs
and c) inactivation of MDSCs

110

(Figure 1.4). Several of these strategies have been

developed and are currently being tested in the clinic.

Figure 1.4. Therapeutic strategies to target MDSCs. The main strategies to target
MDSCs involved the elimination, inactivation or blocking the accumulation and inducing
the differentiation of MDSCs. First, preclinical and clinical studies have shown that
MDSCs can be eliminated with low doses of chemotherapeutic drugs and with TRAIL
agonist resulting in MDSC cell death. Secondly, in vivo inactivation of MDSCs by
targeting their immunosuppressive machinery has been demonstrated in several studies.
PDE-5. NO-realizing aspirin, triterpenoids and COX-2 inhibitors had shown to inhibit
MDSCs function by reducing ROS, RNS and arginase levels. Finally, MDSCs
accumulation can be inhibited by in inducing their differentiation into terminally
differentiated cells with immunostimulatory activity. Differentiation of MDSCs to
immunostimulatory myeloid cells using ATRA have shown efficacy in cancer patients.
19

Elimination of MDSCs has shown to enhance antitumor efficacy of cancer
immunotherapy including adoptive T cell transfer.

111

Conventional anticancer agents, in

addition to their direct effect on cancer cells, have demonstrated the depletion of MDSCs
in tumor-bearing hosts. Gemcitabine was the first chemotherapy agent reported to be
capable of eliminating MDSCs in tumor models.

112

This study demonstrated that

elimination of MDSCs by gemcitabine improves antitumor responses and enhances the
effects of immune therapy resulting in tumor regression. Other chemotherapeutic drugs
showing elimination of MDSCs include 5-fluorouracil, cistaplin, doxorubicin and others
113,114,115

. Another strategy to eliminate MDSCs is by targeting TNF—related apoptosis

induced ligand-receptors (TRAIL-R).

116

It was shown that upregulation of TRAIL-R,

especially DR5, regulates MDSCs survival in tumor-bearing host, and by using a TRAILR agonist, MDSCs were selectively eliminated leading to a decrease in tumor growth in a
CD8+ T cell-dependent manner. Results from a phase 1 trial showed promising data that
supports the use of TRAIL-R agonist in cancer patients. 117 Recently, a novel therapeutic
approach to target MDSCs was developed by genetically fusing S100A9-derived peptides
with the antibody Fc portion to generate a peptibody.

118

These peptibodies successfully

depleted MDSCs from blood, spleen and tumors of mouse models. However, future
studies are needed to further elucidate the mechanisms of action that leads to MDSCs
elimination (Figure 4).
MDSCs use several mechanisms to suppress anti-tumor immune responses and
targeting the suppressive machinery of MDSCs has been tested in cancer patients.
Increased production of ROS and NO by MDSCs plays a major in the suppression of
20

CD8+ T cell responses. Inhibitors for the production of ROS using ROS scavengers Nacetylcysteine (NAC) and catalase are commonly used to test the function of mouse and
human MDSCs ex vivo. NF erythroid 2-related factor 2 (NRF2) is a transcription factor
involved in the activation of the antioxidant response and in protecting cells against
damage caused by ROS. Upregulation of NRF2 by a synthetic triterpenoid was able to
neutralize human MDSCs activity by reducing production of ROS and dampening their
suppressive function ex vivo.

119

However, a recent study from Beury et al. showed that

Nrf2-/- MDSCs had a decrease in their suppressive activity compared to Nrf2+/+ MDSCs
in two mouse models. 120 Scavengers of NO, such as carboxy-PTIO (C-PTIO), have been
tested recently for MDSCs. Treatment with C-PTIO decreased the function of MDSCs
and improved the efficacy of adoptive T cell transfer in tumor-bearing mice.

121

Besides

blocking ROS and NO, another approach to inactivate MDSC function is to inhibit the
catabolic enzymes upregulated by MDSCs including Arg1 and iNOS which are
implicated in the suppression of T cell activation and proliferation. 65 Inhibitors for Arg1
and iNOS have been used extensively in functional assays for MDSCs. Early studies by
Rodriguez et al., demonstrated that a specific inhibitor for Arg1, N-hydroxyl-nor-L-Arg
(nor-NOHA) could inhibit tumor growth and decrease Arg1 levels in MDSCs. 65,122 Arg1
inhibitor, as well as iNOS inhibitor

L-NG-monomethyl-L-arginine

(L-NMMA), had

shown to reduce MDSCs function and improve T cell proliferation in vitro. Moreover,
both Arg1 and iNOS levels in PBMCs of cancer patients have been shown to decrease in
response to phosphodiesterase-5 (PDE5). Several PDE5 inhibitors had been used in the
clinic to treat cancer and other conditions showing a decrease in MDSCs numbers. 123,124
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Recently, a clinical report indicated that head and neck cancer patients treated with the
PDE5 inhibitor tadalafil had a reduction in MDSCs and the expression of both Arg1 and
iNOS, associated with an increase of T cells.

125

A parallel study demonstrated that

treatment with tadalafil decreased not only MDSCs but also Tregs in blood and tumors of
patients with head and neck squamous carcinoma.

126

Also, these patients treated with

PDE5 inhibitor had an increase in tumor-specific CD8+ T cells. Nitroaspirin, a NOreleasing aspirin, has been shown to induce downregulation of both Arg1 and iNOS, and
PNT in MDSCs from a colon carcinoma model.

127

Since nitroaspirin was poorly

effective as an adjuvant for adoptive T cell transfer, Molon et al. developed AT38 ([3(aminocarbonyl)furoxan-4-yl]methyl salicylate) to inhibit reactive nitrogen species in
MDSCs. 20 In this study, AT38 was shown to inhibit Arg1, iNOS and PNT in MDSCs as
well as inhibition of CCL2 nitration leading to an increase in CD8+ T cells within the
tumor microenvironment. Another major mechanism of immunosuppression by MDSCs
is the production of PGE2 through activation of COX-2.

128

Several COX-2 inhibitors,

including celecoxib, have demonstrated a reduction in PGE2 production and inhibition of
Arg1 and iNOS in MDSCs from different mouse models.

128,16,71

Selective COX-2

inhibition by celecoxib reduces MDSC numbers and production of ROS and NO and
improved a dendritic cell-based immunotherapy in a mesothelioma model. 71 (Figure 4).
In addition to eliminating MDSCs or targeting their immunosuppressive machinery,
blocking expansion and inducing differentiation of MDSCs is another therapeutic
strategy with potential. It is well established that tumor-secreted factors play a critical
role in preventing the differentiation of MDSCs into dendritic cells or macrophages.
22

129,130

The differentiation of MDSCs into mature myeloid cell was initially shown by in

vitro and in vivo treatment with all –trans retinoic acid (ATRA), a natural oxidative
metabolite of vitamin A.

131,132

Cancer patients treated with ATRA had an improvement

in their myeloid/lymphoid dendritic cell ratio and immune responses. 133 The mechanism
involved in MDSCs differentiation by ATRA involves the activation of ERK1/2 MAPK
kinase that up-regulates the expression of glutathione synthase increasing the synthesis of
glutathione.

134

Accumulation of glutathione in MDSCs by ATRA reduces the levels of

ROS leading to MDSC differentiation into mature myeloid cells. Depletion of MDSCs by
ATRA enhanced the effects of a cancer vaccine in patients with extensive stage small cell
lung carcinoma 135. Moreover, treatment with ATRA demonstrated a reduction of MDSC
levels and function, and improved chimeric antigen receptor (CAR) therapy responses in
a sarcoma model. 136

Conclusions
The field of MDSC research has dramatically gained more attention over the
past 10 years. MDSCs are critical for the regulation of immune responses in cancer and
other pathological conditions. These cells may serve as a powerful biomarker for the
selection of immunotherapies or anticancer therapies for cancer patients. In addition,
eradicating MDSCs from cancer patients could improve the effects of recent and
upcoming cancer immunotherapies.
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CHAPTER TWO: UNIQUE FEATURES OF MDSCS IN CANCER

Introduction
One of the hallmarks of cancer is the expansion and accumulation of highly
immunosuppressive myeloid cells known as myeloid-derived suppressor cells
(MDSCs)1,3. MDSCs are a heterogeneous population of bone marrow-derived immature
myeloid cells that accumulate in peripheral lymphoid organs and tumor tissues. The
expansion of MDSCs correlates with a poor prognosis and clinical outcome in cancer
patients6. The main feature of MDSCs is their ability to suppress anti-tumor immune
responses2, which leads to tumor progression, angiogenesis and metastasis4,5. During
this chapter, we will describe two studies that helped clarify the phenotypic distinction
between PMNs and PMN- MDSCs and their role in MDSC migration to metastatic sites
in cancer.
As a group of immature cells, MDSCs are subdivided into two main populations:
polymorphonuclear

MDSC

(PMN-MDSC,

CD11b+Ly6G+Ly6Clow)

and

monocytic MDSC (M-MDSC, CD11b+Ly6G-Ly6Chigh) cells1,3. In humans, MDSCs can
be identified after density gradient centrifugation followed by flow cytometry using
markers expressed by their normal myeloid counterparts. Human PMN-MDSCs are
defined as CD11b+CD14-CD15+ or CD11b+CD14-CD66b+ whereas M-MDSCs are
defined as CD11b+CD14+HLA-DR-/loCD15-

10,12

. In most types of cancers, both mice

and human PMN-MDSCs are the most abundant population of MDSC. Moreover,
PMN-MDSC and M-MDSC are morphologically and phenotypically similar to
neutrophil and monocytes, respectively28. MDSCs have the ability to suppress anti24

tumor immune responses, an important characteristic that is absence in their
counterparts, PMNs and monocytes. Therefore, the criteria established to define cells as
MDSCs should always include phenotypic and functional characteristics. Although there
is consensus for these criteria, markers to identify MDSC are needed to fully
characterize this immune cell population. In addition, the drivers that promote their
migration to metastatic sites and development of MDSC generation in cancer remain
poorly defined.

A marker for MDSCs in cancer
Introduction. One of the main questions in the MDSC field is the issue of their
heterogeneity in cancer. PMN-MDSCs are not only the most abundant population of
MDSCs, but isolation of these cells from peripheral blood (PB) also enriches nonsuppressive PMNs. At the present, separation of PMN-MDSCs and PMNs from
tumors is not possible, therefore, this complicates the analysis of these cells.
Results. The standard method to isolate PMN-MDSCs is by dual-density
Histopaque gradient, in which low-density PMN-MDSCs are copurified with peripheral
blood mononuclear cells (PBMCs), whereas high-density PMNs are collected from
lower gradient 10,12,81. As control, PMNs from healthy donors are used after Histopaque
to compare with PMN-MDSCs or PMNs from cancer patients. Immunosuppressive
activity by PMN-MDSCs and PMNs has been tested in allogeneic mixed leukocyte
reaction (MLR) or in autologous system with T cells activated by CD3/CD28
antibodies. As expected, only PMN-MDSCs were suppressive. Therefore, to determine
the overall differences and similarities between patients’ PMNs and PMN-MDSCs as
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well as PMNs from healthy donors, whole-genome analysis was performed. In general,
PMN-MDSCs had a distinct genomic profile from PMNs isolated from the same
cancer patients and PMNS from healthy donors. Molecules involved in immune
suppression included low-density lipoprotein (LDL) and genes associated with
endoplasmic reticulum (ER) stress, which were among the most up-regulated in PMNMDSC compared to PMN12.
To identify a potential marker of PMN-MDSCs, surface molecules were compared
with PMNs from the same patients and PMNs from healthy donors. Main differences
were found in the expression of lectin-type oxidized LDL receptor-1 (LOX-1), a 50kDa transmembrane glycoprotein encoded by the oxidized LDL receptor 1 (OLR1)
gene137. LOX-1 is one of the main receptors for oxidized LDL (oxLDL), which is
associated with endothelial cells, macrophages, smooth muscle cells and some intestinal
cell lines, but not with neutrophils137,138. However, LOX-1 expression defined distinct
population of neutrophils in cancer patients and was associated with accumulation of
PMN-MDSC.
To further determine whether LOX-1 can be a marker for human PMNMDSCs, LOX-1+ and LOX-1− PMNs were sorted directly from PB of the same cancer
patients. Interestingly, LOX-1−PMN had the typical morphology of mature neutrophils,
whereas LOX-1+
shaped

PMN

displayed

more

immature

morphology

with

band-

nuclei. Moreover, whole-gene expression analysis was performed, and it was

found that on the basis of the expression of genes analyzed, LOX-1+ PMNs clustered
together with PMN- MDSCs, whereas LOX-1− PMNs were very similar to patients’ and
healthy donors’ PMNs. In addition, immune suppressive activity was tested, LOX-1+
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PMNs suppressed T cell proliferation, whereas LOX-1− PMNs did not. When immune
suppressive mechanisms were evaluated, LOX-1+ PMNs showed higher expression of
arginase 1 and production of reactive oxygen species than LOX-1− PMNs. Thus, these
data demonstrate that LOX-1+ PMNs represent a population of PMN- MDSCs.
Interestingly, in contrast to humans, LOX-1 was not associated with PMN-MDSCs from
tumor-bearing mice12.
To answer the question of what induces LOX-1 up-regulation, PMNs from
healthy donors were exposed to proinflammatory cytokines [IL-1b, TNF-alpha, and IL6] or tumor-conditioned media. None of these factors induced up-regulation of LOX-1
in PMNs. Based on previous observations81 and data obtained from the whole-gene
analysis, it was demonstrated that PMN-MDSC and LOX-1+ PMNs in cancer patients
displayed signs of ER stress response. LOX-1+ PMNs had significantly higher
expression of spliced X-box–binding protein 1 (sXBP1) and activating transcription
factor 4 (ATF4), but not CCAAT/enhancer binding protein (CHOP).
To test the effect of ER stress on the expression of LOX-1, PMNs from healthy
donors were treated with ER stress inducer, thapsigargin (THG). THG not only upregulated LOX-1 expression but it also made PMNs highly immunosuppressive. To
further verify the role of ER stress in the up- regulation of LOX-1 and acquisition of
immune suppressive activity by THG-treated PMNs, a selective inhibitor of sXBP1, BI09, was used139. In the presence of BI09, THG was not able to induce up-regulation of
LOX-1 and immunosuppressive activity of PMN. Thus, induction of ER stress in control
neutrophils converted these cells to immunosuppressive PMN-MDSCs, which were
associated with upregulation of LOX-1 expression12.
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Figure 2.1. Up-regulation of LOX-1 receptor in PMN-MDSCs from cancer patients.
1) In cancer, PMN-MDSCs are challenged by different stress conditions including
hypoxia, lack of nutrients, low pH and other mediators. 2) Upon stress conditions, ER
stress response is developed which further activate three major signaling cascades
including Xbp1. 3) Xbp1 mediates the up-regulation of LOX-1 on the surface of PMNMDSCs. 4) At the same time, Xbp1 activation is implicated in the up-regulation of
arginase 1 (Arg1) and increased production of reactive oxygen species (ROS), which are
key mediators of immune suppression by PMN-MDSCs in cancer. 5) Up-regulation of
LOX-1 in PMN-MDSCs could lead to their acquisition of immunosuppression, however,
this remains unclear.

There is now sufficient evidence demonstrating that tumor MDSCs are more
immune suppressive than cells in PB9. To evaluate the presence of LOX-1+ PMN-MDSC
in tumor tissues, a method of immunofluorescence staining of paraffin embedded
tissues with the combination of LOX-1 and CD15 antibody, was tested. Compared to
control tissues, the number of LOX-1+ CD15+ PMN-MDSCs in colon carcinoma
increased more than 8-fold, in HNC more than 10-fold, and in NSCLC almost 8fold. Thus, LOX-1 expression defined the population of PMN-MDSCs in tumor
tissues. To determine the clinical association of LOX-1 expression in PMN-MDSCs
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from tumor tissues, Oncomine and TCGA (The Cancer Atlas) databases were evaluated.
Although OLR1 was significantly up-regulated in different types of cancer, the
interpretation had some limitations in defining the association with PMN-MDSC since
other cells c a n express ORL1/LOX-1. However, it was found that patients with late
stages of cancer or larger tumors had a significantly higher proportion of LOX-1+
PMN-MDSC than healthy donors. Thus, this data suggests that LOX-1 is a specific
marker of PMN-MDSCs in cancer patients (Figure 2.1)12.

Discussion. MDSCs are now recognized as one of the critical contributors to
immune suppression in cancer. Although, there are still some main controversies
associated with MDSC since their discovery that need to be address, the described
studies have helped to further our understanding of MDSC in cancer.
Given that MDSCs are morphologically and phenotypically similar to neutrophils
and monocytes, their lack of specific markers has limited progress in our understanding
of the biology of these cells. Therefore, the goal of this study was to address the issue of
heterogeneity of MDSCs. In this study, PMN-MDSCs demonstrated a unique gene
expression profile compared to PMNs from the same patients and from healthy donors,
which is consistent with the analysis of gene expression in tumor-bearing mice
compared to tumor-free mice89. Up-regulation of genes associated with ER stress was
one of the main features present in PMN-MDSCs, which was demonstrated
previously in mice where MDSCs displayed several of the hallmarks of ER stress in
tumor-bearing mice and cancer patients81. Here, it was determined that the expression of
LOX-1 receptor not only was associated with but also defines the population of human
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PMN-MDSCs. LOX-1+ PMN-MDSCs were present in tumor tissues, opening an
opportunity for a direct identification of these cells not only in peripheral blood but
also tumors of cancer patients. Moreover, it was shown that induction of ER stress in
neutrophils from healthy donors caused an up-regulation of LOX-1, which fits the
overall concept of the critical role of ER stress response in MDSC biology. Recent
studies have confirmed these observations in other cancer types, such as glioblastoma155.
Although specific markers of MDSCs in mice are still absent, it is possible that
LOX-1 expression is regulated differently in mice and humans, but this remains unclear.
Another interesting question is whether LOX-1 is express in M-MDSCs in cancer
patients which requires further study. However, at the present, expression of LOX-1 on
PMN-MDSC opens an opportunity for specific identification and selective targeting of
these cells in cancer patients.

Unique pattern of MDSC migration in cancer
Introduction. Although there has been some progress in defining the differences
between PMN- MDSCs and PMNs, their role is still controversial in cancer. Besides the
role of PMN- MDSCs in suppressing anti-tumor immune responses, along with
PMNs, they are also implicated in metastasis, which is the leading cause of mortality
in cancer4. Moreover, PMN-MDSC can condition the primary metastatic site for
tumor cells through several pathways including production of hepatocyte growth factor,
TGF-β, matrix metalloproteinase 9, S100A8/A9, and direct immunosuppressive activity
which promotes metastasis

140-146

. However, the mechanism of the initial events that

leads to the formation of the pre-metastatic niche remained unclear.
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Migration

and

recruitment of

neutrophils to

sites

of

inflammation is

a

fundamental characteristic of these cells, which is directed by cytokines, chemokines and
others

147,148

. Although recruitment of PMN-MDSC to tumor tissues is well-

documented 9, their migration to metastatic sites and differences with neutrophils are not
clear yet. Interestingly, it has been reported that PMN-MDSCs migratory activity
is reduced and impaired in the peripheral blood of cancer patients. Therefore, this study
was designed to clarify the role of neutrophils and PMN-MDSCs functions and
mechanisms that lead to their migration to pre-metastatic sites in tumor-bearing mice
and cancer patients149.
First, to evaluate the migration state of neutrophils in cancer, they were isolated
from bone marrow (BM) of three different genetically-engineered models (GEM) of
cancer including, RET melanoma150, KPC pancreatic cancer151, and TRAMP
prostate cancer152. The migration and chemotaxis of neutrophils were assessed by a
standard Transwell membrane assay. Although substantial migration of neutrophils
from tumor- bearing mice in response to chemokine (CXCL1) or chemoattractant
(fMLP) was observed, they also had much more spontaneous migration than neutrophils
from tumor- free littermates (control mice). However, the changes in motility were not
associated with the population expansion of neutrophils in BM and was not entirely
associated with expression of the CXCL1 receptors CXCR1 and CXCR2. The
differences observed in BM neutrophils migration were also noticed on isolated
neutrophils from the peripheral blood of RET mice compared to their control
counterparts. When BM neutrophils from models of mice given subcutaneous
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transplantation of tumors (EL4 lymphoma, LLC lung carcinoma and CT26 colon
carcinoma) were evaluated for their migratory capacity, no differences were observed
compared to control mice149.
Since there were no changes in migration by neutrophils from transplantable models
of subcutaneous tumors, it was hypothesized that it was possibly due to inflammation
caused by the injection of large number of tumor cells. To overcome this problem, an
orthotopic model of lung cancer that involves intravenous injection of a small number
of luciferase-expressing LL2 (Lewis lung carcinoma) tumor cells was used. Within one
week after injection of tumor cells, tumor lesions form in the lungs (“1-week mice”) and
larger lesions are observed at 3 weeks after injection (“3-week mice”). In 1-week mice,
BM neutrophils had much greater spontaneous and CXCL1-induced migration than
neutrophils from 3-week mice or control mice. To confirm these observations in vivo,
BM neutrophils from congenic LL2 tumor-bearing mice (CD45.1+) and tumor-free
(CD45.2+) mice (control mice) were mixed at a ratio of 1:1 and injected intravenously
into CD45.1+CD45.2+ tumor-free recipient mice. As observed in vitro, neutrophils from
1-week mice were more prevalent than control or 3-week neutrophils in the spleen and
lungs, which suggested that they have an increase in their migratory ability. Moreover,
when neutrophils were compared in KPC mice with pancreatic intraepithelial neoplasia
(PanIN; early stage) or pancreatic ductal adenocarcinoma (PDA; late stage), those from
PanIN had greater spontaneous migration than those with late stage PDA.
Interestingly, the results of gene expression profiling by RNA sequencing suggested
that BM neutrophils in 3-week mice, but not in 1-week mice, are actual PMN-MDSCs.
These observations were confirmed by immune suppressive activity and cytokine
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profile suggesting that neutrophils from 3-week mice are indeed PMN-MDSCs,
whereas neutrophils from 1-week mice were described as PMN-MDSC-like cells
(PM-LCs). This term has been used before to describe a population of activated
neutrophils in cancer with lack of immune suppressive activity149.
Another mechanism evaluated to further characterize the differences between
PM-LCs and PMN-MDSCs was their metabolic state. First, seahorse analysis showed
that BM PM-LCs from 1-week LL2 or RET mice had markedly higher oxygenconsumption rate (OCR) and extracellular acidification rate (ECAR) than neutrophils
from 3-week or control mice. Thus, BM PM-LCs from early stages of orthotopic lung
cancer and from RET mice had greater oxidative phosphorylation and glycolysis than
PMN-MDSCs or control neutrophils. Given the difference in glycolysis, metabolomics
analysis of

13

C6-glucose was performed in neutrophils from control and PM-LCs from

1-week TB mice. BM PM-LCs had more uptake of glucose, along with higher
intracellular levels of pyruvate, citrate and lactate, than that of control neutrophils. In
addition, there was greater flux of glucose carbon through glycolysis and into the
tricarboxylic acid (TCA) cycle in PM-LCs compared to control. Due to an increase in
glycolysis and flux through the TCA cycle, PM-LCs had significant high levels of ATP.
It has been reported that neutrophils have few mitochondria and rely on glycolysis to
generate ATP153, therefore, it was found that PM-LCs had higher expression of the
glucose transporter Glut1 along with an increased glucose uptake by PM-LCs compared
to neutrophils from tumor-free mice149.
To determine if PM-LCs migration is mediated by ATP, two experiments were
performed: 1) inhibition of ATP-mediated autocrine signaling by using pannexin-1
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mimetic inhibitory small peptide (10Panx) to inhibit pannexin-1 hemichannels that is
responsible for ATP release and 2) treatment with apyrase, an enzyme that catalyzes the
hydrolysis of ATP. After treatment with either
migration

of

PM-LCs

was

completely

10

Panx or apyrase, the spontaneous

abolished.

Several

ATP

receptors

(purinergic; P2X1, P2Y1 and P2Y2) were selectively inhibited, but only blockage of
P2Y1 and P2Y2 completely abolished the increase spontaneous migration by PM-LCs,
whereas P2X1 inhibitor
migration

only

caused

a

partial (50%) reduction. Neutrophil

requires polarization of the front and rear of the cell, processes that are

coordinated by the activation of several guanosine triphosphatases (GTPases) that lead
to actin polymerization154. No difference was found in the polymerization of actin in
PM-LCs or neutrophils. Activation of kinase ROCK, which phosphorylates regulatory
myosin light chain MLC2148, is involved in the migration of neutrophils. Notably, it was
found that there was a substantial upregulation of phosphorylated MLC2 in PM-LCs
from 1-week mice compared to control neutrophils. Thus, increased spontaneous
migration of PM-LCs is regulated by ATP and requires the phosphorylation of MLC2 in
cancer149.
To translate this observation in mice to humans, neutrophils were isolated from
healthy donors and cancer patients. Neutrophils from cancer patients demonstrated much
greater

spontaneous

or

chemokine-induced migration

compared

to

controls.

However, there were no significant changes in the expression of chemokine receptors
CXCR1 and CXCR2.
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Figure 2.2. Migration and mechanisms associated in PMNs, PM-LCs and PMNMDSCs. In tumor-bearing host, PMNs are steady in bone marrow or in the periphery.
However, when tumor arises, a population of activated neutrophils, named PMN-MDSClike cells (PM-LCs), presented a much greater spontaneous migration at early stages of
cancer compared to tumor-free (control) This unique pattern of migration by PM-LCs is
mediated by increased in oxidative phosphorylation, glycolysis and high ATP levels. As
tumor progress, PM-LCs are recruited into peripheral organs or tumor tissues where they
become PMN-MDSCs. At late stages, PMN-MDSCs do not have any sign of oxidative
phosphorylation or glycolysis but they acquired potent immune suppressive activity. ATP
levels in PMN-MDSCs remains unknown.
When CD15+ neutrophils were isolated from the high-density (PMNs) and the
low-density (PMN-MDSCs) fraction from the same patient, only PMN exhibited
substantially greater migration than PMN-MDSCs. Altogether, these data suggest that
neutrophil from 1-week tumor-bearing mice and cancer patients are more migratory than
PMN-MDSCs or PMNs from controls or healthy donors, respectively (Figure 2.2)149.
Discussion. It is now clear that one of the hallmarks of cancer is the expansion
and accumulation of MDSCs in peripheral organs and tumor tissues of tumor-bearing
mice and cancer patients. In tumor-bearing hosts, MDSCs are generated in the bone
35

marrow followed by their infiltration into peripheral organs and tumor tissues.
Recruitment of MDSCs to these tissues are controlled by different factors that may
depend on the tumor microenvironment. However, their migration to pre-metastatic
sites and their differences compared to neutrophils remain unclear. Moreover, there
has been no clear evidence whether MDSCs have a unique pattern of migration
compared to their normal counterparts until this study which has helped to clarify this
issue. One of the first observations of this study, was the description of a population of
activated neutrophils in the bone marrow with an ability to migrate into spontaneously
arising cancer. These cells were consistently different from classic neutrophils and
PMN-MDSCs, due to their spontaneous migration and lack of immune suppressive
activity, respectively. In addition, these cells were present only at early stages of cancer
(1-week mice); had increased expression of genes encoding molecules associated
with ER stress, energy production, oxidative phosphorylation and glycolysis; and
they had more ATP t h a n control neutrophils i s o l a t e d from tumor-free mice.
Therefore, these BM neutrophils were described as “PMN-MDSC-like cells” (PM-LCs),
a term that describes their functional state at early stages. The potent ability of PM-LCs
to spontaneously migrate was maintained by coordinated GTPase signaling molecules
that were the driving force supporting the increase in their migratory activity.
Furthermore, it was demonstrated that the increase in ATP level was directly driving the
spontaneous migration of BM PM-LCs at early stages. Although metabolism of MDSCs
in cancer is not well understood, it is known that tumor-infiltrating MDSCs have an
increase in glycolysis rates that drive their metabolism toward fatty-acid oxidation
(FAO)149. Therefore, the data demonstrated in this study suggest that the increased
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metabolism and ATP in BM PM-LCs precedes their acquisition of the functional
immunosuppressive characteristics of bona fide PMN-MDSCs. In line with the
observations at early stages in tumor-bearing mice, peripheral blood neutrophils from
cancer patients have a greater spontaneous migration compared to neutrophils from
healthy donors. Thus, this study elucidates novel mechanisms that lead to neutrophil
spontaneous

migration

and

their

contribution

37

at

early

stages

of

cancer.

CHAPTER 3: IMMUNE SUPPRESSIVE ACTIVITY OF MDSCS IN CANCER
REQUIRES INVACTIVATION OF THE TYPE 1 INTERFERON PATHWAY

Introduction
Myeloid-derived suppressor cells (MDSC) are pathologically activated neutrophils
(PMN) and monocytes (Mon) with potent immune suppressive activity. These cells have
a distinct transcriptional profile, biochemical features and, most importantly, exhibit
potent ability to suppress immune responses

156

. The total population of MDSC consists

of three groups of cells: the most abundant (>75%) relatively immature, pathologically
activated neutrophils (PMN-MDSC); the less abundant population of pathologically
activated monocytes – (M-MDSC); and small population of early myeloid precursors
present in humans

10

. MDSC accumulation is described in many pathologic conditions,

but they play an especially prominent role in cancer as major regulators of immune
responses and one of the limiting factors for cancer immunotherapy. In recent years, the
clinical role of MDSC has emerged. Results showed positive correlation of MDSC in
peripheral blood with cancer stage and tumor burden in many types of cancer

157-159

.

Elevated MDSC in the circulation were found to be an independent indicator of poor
outcomes in patients with solid tumors 102. Recent studies demonstrated values of MDSC
in predicting response to therapy in many types of cancer160-166. The circulating MDSC
negatively correlated with objective clinical response to check-point inhibitors

109, 167-169

.

In tumor mouse models, MDSC inhibition during immunotherapy increases its
therapeutic effect 108, 170-174.
The current paradigm stipulates that PMN and Mon acquire immune suppressive
features during their differentiation as a result of the direct effect of various tumor38

derived factors and tumor microenvironment. Several cytokines and growth factors, as
well as number of transcriptional factors and signal transduction pathways, were
implicated in promotion of immune suppressive function of MDSC

175

. However, recent

studies demonstrated that only a fraction of PMN (usually around 5-10% in peripheral
blood and 60-70% in tumor tissues) in cancer patients acquires features of MDSC12. The
fact that the proportion of MDSC in cancer patents correlated with clinical outcome also
indicates that MDSC represent only part of populations of PMN and Mon. This raises an
important question: why do tumor-derived factors abundantly present in tumor-bearing
hosts not affect all cells? We hypothesized that in addition to “positive” signals that
promote MDSC, there are also “negative” signals that limit the acquisition of MDSC
features by PMN and Mon. Furthermore, these negative regulatory mechanisms are
expected to be somehow inactivated in myeloid cells exposed to the stimuli derived from
malignant cells or/and present in the tumor microenvironment.
During the analysis of previously obtained MDSC gene expression profile data we
noticed a substantial down-regulation of the type I interferons (IFN1) pathway

90

. IFN1

(including IFN-α and IFN-β) act on cells by engaging a cognate receptor (consisting of
two chains, IFNAR1 and IFNAR2) and triggering the signal transduction pathway that
involves activation of TYK2/JAK1 Janus kinases, phosphorylation and activation of
STAT1/STAT2 heterodimer. The latter interacts with IRF9, translocates to the nucleus
and transactivates IFN1-stimulated genes

176-179

. IFN1 are known to promote anti-tumor

immunity by diverse mechanisms including stimulation of DC maturation and antigen
presentation and improving the survival of cytotoxic lymphocytes
suggested to enhance the effect of cancer immunotherapy
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177,183

179-182

. IFN1 is

. Tumor-derived factors

(such as pro-inflammatory cytokines

184

or extracellular vesicles

tumor microenvironment (deficit of oxygen or amino acids

186

185

and stimuli of the

) inactivate the IFN1

pathway via prompting the p38 kinase-dependent phosphorylation, ubiquitination and
degradation of IFNAR1 182,187,188. However, the role of IFN1 in the regulation of numbers
and suppressive activities of MDSC remains poorly understood.
Furthermore, the literature on the role of IFN1 in control of MDSC is rather
controversial. Reports suggesting that IFN1 stimulate the generation

189

or suppressive

activities of MDSC via sustaining expression of PD-L1 190 are contradicted by the studies
where administration of IFN1 inducers such as poly(I:C) or CpG led to decreased
numbers or/and undermined suppressive activities of MDSC

191-193

. Whereas activation

of STING and ensuing production of IFN1 by tumor irradiation was suggested to induce
MDSC

194

, the opposite results were reported by studies using forced expression of

STING; however, the latter effects were not dependent on IFN1

196

. Thus, the critical

questions regarding the possible role of IFN1 in regulation of MDSC suppressive activity
as well as the mechanisms by which the effects of IFN1 on MDSC are inactivated in the
tumor microenvironment remains to be answered.
Here, we report that mouse and human MDSC exhibit a substantially reduced
expression of IFNAR1 on their surface compared to PMN and Mon. This resulted in
inhibition of IFN1 pathway. Loss of IFNAR1 alone was not sufficient to convert PMN or
Mon to MDSC; however, preventions of IFNAR1 degradation abrogated MDSC activity
and had potent antitumor effect.

40

Results
MDSC in cancer patients and tumor-bearing mice exhibit low expression of type
I interferon receptor. Careful analysis of previously obtained transcriptome of mouse
spleen PMN and PMN-MDSC

90

revealed a substantial down-regulation of the IFNAR1

mediated pathway in PMN-MDSC (Fig. S3.1A). We found 911 genes that were
significantly downregulated (FDR<20%) in PMN-MDSC compared to PMN. Among
these genes, there was a significant enrichment of interferon induced genes (2.4-fold over
random chance, p=7x10-6 by Fisher Exact Test). Similar observations were made during
the analysis of transcriptome of blood PMN and PMN-MDSC (based on LOX-1
expression) in cancer patients

12

(Fig. S3.1B). These results suggested that the IFN1

pathway is suppressed in the PMN-MDSC in cancer patients and this phenotype is
recapitulated in the PMN-MDSC from the tumor-bearing (TB) mice.
All response to IFN1 are determined by the cell surface levels of the IFN1 receptor,
which, in turn, is controlled by ubiquitination and degradation of its IFNAR1 chain
197-198

181,

. We compared IFNAR1 expression on the surface of PMN and Mon from healthy

donors and patients with non-small cell lung cancer, pancreatic cancer, breast cancer,
head and neck cancer, and colon cancer (Fig. S3.2A). Although several patients
demonstrated decreased expression of IFNAR1 in Mon as compared to healthy donors, in
the entire group, the differences were not statistically significant (Fig. 3.1A). In contrast,
cancer patients’ PMN-MDSC demonstrated markedly lower expression of IFNAR1 than
PMN from healthy donors (Fig. 3.1A). Those differences in IFNAR1 expression were
largely associated with the presence of MDSC in cancer patients. When Mon and MMDSC as well as PMN and PMN-MDSC were compared in the same patients separated
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using established phenotypic criteria 10 (Fig. S3.2B), a substantially lower amounts of the
IFNAR1 on M-MDSC and PMN-MDSC than Mon and PMN was observed (Fig. 3.1B).
Notably, the decrease in IFNAR1 expression was more pronounced in PMN-MDSC than
in M-MDSC.
A similar analysis was performed on mouse MDSC, which were gated using
established

criteria:

PMN-MDSC

-

CD11b+Ly6CloLy6G+,

M-MDSC

-

CD11b+Ly6ChiLy6G- 10. Cells with the same phenotype in naïve, tumor-free mice were
defined as PMN and Mon respectively (Fig. S3.2C). We assessed the expression of
IFNAR1 in MDSC from transplantable models of B16 melanoma, LLC lung carcinoma,
CT26 colon carcinoma (Fig. 3.1C) and genetically engineered models of melanoma
(RET) and pancreatic cancer (KPC) (Fig. 3.1D). In transplantable models, spleen PMNMDSC demonstrated markedly lower expression of IFNAR1 than PMN with the same
phenotype from tumor-free mice. Although in some models there was a clear trend in
decrease of IFNAR1 expression in M-MDSC as compared to Mon, it did not reach
statistical significance (Fig. 3.1C). In RET and KPC models, PMN-MDSC demonstrated
a modest but significant decrease in IFNAR1 expression, whereas M-MDSC retained the
same level of the receptor as control Mon (Fig. 3.1D). To safeguard against potential
IFNAR1 cleavage by proteases

199

, we avoided enzymatic tumor digestion by using

ascites of EL4 and MethA sarcoma tumors where myeloid cells can be directly isolated
from the tumor site. We observed dramatically reduced expression of IFNAR1 on the
surface of tumor PMN-MDSC and M-MDSC than on spleen cells (Fig. 3.1E). We also
used mechanical disruption of LLC and KPC tumors without enzymatic digestion to
recover PMN-MDSC. IFNAR1 expression in tumor PMN-MDSC was substantially lower
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than in spleen PMN-MDSC (Fig. 3.1F). Down-regulation of IFNAR1 in PMN-MDSC
and M-MDSC was associated with dramatically lower expression of the IFN1-inducible
genes such as Irf7 (Fig. 3.1G) and Isg15 (Fig. 3.1H). Thus, both populations of MDSC in
blood of cancer patients, as well in tumors of TB mice and PMN-MDSC in spleens of TB
mice had marked inhibition of the IFN1-IFNAR1 pathway.

Figure 3.1. IFNAR1 is downregulated in MDSCs. (A) IFNAR1 levels on CD15+ PMN
(left) and CD14+ Mon (right) from whole blood of healthy donors (HD) or cancer patients
(CP). Individual results in 6 healthy donors and 22 cancer patients are shown. IFNAR1
levels is presented as geometric mean. (B) IFNAR1 measured on PMN versus PMNMDSCs (n=3) or Mon versus M-MDSCs (n=4) from the same patients. Fold change from
IFNAR1 level in PMN or Mon in each patient is shown. (C) IFNAR1 levels on mouse
splenic PMN-MDSCs and M-MDSCs from indicated s.c. tumor models analyzed by flow
cytometry. Each dot represents geometric mean of IFNAR1 levels in individual mouse
(n=4-6). (D) IFNAR1 levels on splenic PMN-MDSCs and M-MDSCs from spontaneous
tumor models analyzed by flow cytometry. Fold change over spleen of tumor-free mice
(n=3-5). Mean and SD are shown. (E) IFNAR1 levels on PMN-MDSCs and M-MDSCs
from spleen and indicated ascites tumors analyzed by flow cytometry. Each dot
represents an individual mouse (n=3-4). IFNAR1 levels is presented as fold changes from
spleen cells. (F) IFNAR1 levels on PMN-MDSCs and M-MDSCs from spleen and
mechanically dissociated tumors analyzed by flow cytometry. Each dot represents
geometric mean of IFNAR1 levels in individual mouse. (n=3-5). G. Irf7 expression in
PMN-MDSCs isolated from spleen of Ret Melanoma and KPC mice (left) or in MMDSCs from EL4 tumor-bearing mice. Each dot represents gene expression as fold
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change over PMNs from spleen of tumor-free mice. (n=3). H. Isg15 expression in PMNMDSCs isolated from spleen of EL4 tumor-bearing mice. Each dot represents relative
expression as fold change of Irf7 in individual mouse from PMN in control mice. In all
panels, data are expressed as Mean ± SEM and the p values were calculated using
unpaired two-sided Student’s t-test. These p values, *p<0.05; **p<0.01; ***p<0.001;
****p<0.0001. ns, not significant.
The biological role of IFNAR1 in MDSC. Given the difference in IFNAR1
levels in tumor and spleen MDSCs, we next compared side by side functional activities
of MDSC in tumors and spleens. Tumor PMN-MDSC and M-MDSC were markedly
more suppressive than spleen MDSC (Fig. 3.2A). This suggested a possible association
between the functional activity of MDSC and expression of IFNAR1. We asked whether
suppressive activity of MDSC could be cancelled by providing high amounts of IFNAR1
ligand – IFNβ. Therefore, we isolated PMN-MDSC from spleen of TB mice and cultured
for 2 hr with IFNβ (2000U), extensively washed and then tested their function in a
suppression assay. This treatment completely abrogated PMN-MDSC suppressive
activity (Fig. 3.2B).
Next, we investigated whether loss of IFNAR1 signaling was sufficient to convert
PMN or Mon to MDSC by using IFNAR1 KO mice. We confirmed lack of IFNAR1
expression in PMN and Mon from IFNAR1 KO mice (Fig. S3.3A). However, PMN or
Mon from tumor-free IFNAR1 KO mice did not have suppressive activity (Fig. 3.2C).
While anti-viral effects of IFN1 can occur at low levels of the IFN1 receptor, even a
modest downregulation of IFNAR1 notably diminishes its immunopathologic activities
188,197

. Thus, we hypothesized that downregulation of IFNAR1 protein in TB mice could

phenocopy genetic ablation of IFNAR1 gene thereby masking the latter phenotype. To
test this hypothesis, we established EL4 tumors in Ifnar1 KO mice. These mice displayed
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markedly accelerated tumor growth as compared to WT mice (Fig. S3.3B) and had the
same proportion and absolute number of spleen PMN-MDSC and M-MDSC as WT TB
mice (Fig. 3.2D). In fact, PMN-MDSC isolated from spleen and tumors of WT and
Ifnar1 KO EL4 TB mice had the same potent suppressive activity (Fig. 3.2E).
Suggesting that genetic deletion of IFNAR1 is not sufficient to make MDSCs more
suppressive in TB mice, since they may have reached their level of immune suppression.

Figure 3.2. Lack of IFNAR1 does not alter immune suppressive activity by PMNMDSCs. (A) Suppression assay of PMN-MDSCs and M-MDSCs isolated from both
spleen and tumors of tumor-bearing mice. PMN-MDSCs (n=3) and M-MDSCs (n=3)
from spleen or tumor were co-culture with antigen-specific CD8+ T cells (OT-1
splenocytes) at different ratios. T cell proliferation was evaluated in triplicate using [3H]thymidine uptake and presented as percentage based on positive control (without
MDSCs), set as 100% proliferation. (B) Suppression assay (as in A) of splenic PMNMDSCs treated for 2h with 2000 U of IFNβ. (C) PMN and Mon were isolated from bone
marrow (BM) of tumor-free WT or Ifnar1 KO mice. Suppression assay was performed as
described in A. (D) Percentage and absolute numbers of PMN-MDSCs and M-MDSCs in
spleen of tumor-bearing mice. (E) Suppressive activity of PMN-MDSCs from spleen and
tumors. Representative of 3 experiments. 100% - proliferation in the absence of MDSC.
In all panels, data are expressed as Mean ± SEM and the p values were calculated using
unpaired two-sided Student’s t-test. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. ns,
not significant.
Then we asked whether prevention of IFNAR1 downregulation could affect
suppressive activity of MDSC. To address this question, we used the knock-in mice that
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express the IFNAR1S526A mutant protein, which is resistant to ubiquitination and
degradation because it lacks critical Ser526, whose phosphorylation enables the
recruitment of β-Trcp E3 ligase

200,201

. All tissues of these animals harbor homozygous

Ifnar1S526A alleles (Ifnar1SA or SA). Naïve Ifnar1SA mice did not exhibit an overt
phenotype (this study and

53

).

MDSC from SA TB mice had substantially higher

expression of IFNAR1 than cells from wild-type (WT) TB mice (Fig. S3.3C). As
expected, PMN-MDSC from SA TB mice had markedly higher expression of Irf7 (Fig.
S3.3D). Consistent with previous observations

182,203

, tumors grew more slowly in SA

mice than in WT mice (Fig. 3.3A). Hematopoietic cells were responsible for the observed
delay in tumor growth since reconstitution of lethally irradiated wild-type recipient mice
with bone marrow from SA mice showed decreased tumor growth as compared to mice
reconstituted with wild-type bone marrow cells (Fig. 3.3B). Proportion of PMN-MDSC
in spleens of SA mice was reduced, however the total number of PMN-MDSC and MMDSC in SA and WT TB mice was comparable (Fig. 3.3C). In contrast to WT TB mice,
neither spleen nor tumor PMN-MDSC in SA TB mice suppressed T-cell proliferation
(Fig 3.3D). Suppressive activity of M-MDSC was also completely abrogated in SA TB
mice (Fig. 3.3E). To determine if the decrease in tumor progression in SA mice was
mediated by CD8+ T cells, we treated mice with anti-CD8 antibody and observed that
depletion of these cells abrogated differences in tumor growth (Fig. 3.3F). However,
depletion of CD8+ T cells did not affect the decrease in the proportion of PMN-MDSC
observed in SA mice (Fig. 3.3G) and did not restore suppressive activity of PMN-MDSC
in SA mice (Fig. 3.3H). Thus, sustained IFNAR1 signaling due to preserved expression
of the receptor in MDSC notably undermined suppressive activity. These results suggest
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that downregulation of IFNAR1 is required but not sufficient for immune suppressive
function of MDSC.

Figure 3.3. Stabilization of IFNAR1 abrogates MDSCs immune suppressive activity.
(A) EL-4 tumor growth in C57BL/6 WT and SA mice (n=4). (B) LLC tumor growth in
mice reconstituted with WT or SA BM cells (n=4). (C) Percentage and absolute number
of M-MDSCs and PMN-MDSCs in spleen of EL4 tumor-bearing mice (n=3). (D)
Suppressive activity by PMN-MDSCs isolated from WT or SA spleen and tumors of EL4
tumor-bearing mice. Splenocytes from OT-1 mice stimulated with cognate peptide were
used as effector cells. 100% - T cell proliferation without PMN-MDSCs; (n=3). (E)
Suppressive activity by M-MDSCs isolated from spleen of EL4 tumor-bearing mice.
100% - T cell proliferation without M-MDSCs; (n=3). (F) EL4 tumor growth in WT and
SA mice depleted of CD8+T cells. Representative of 3 independent experiments. (G)
Percentage of PMN-MDSCs in spleen from WT and SA of EL4 tumor-bearing mice
depleted of CD8+T cells (n=3). (H) Suppressive activity of HPC-derived PMN-MDSCs
generated in vitro. T cell proliferation was evaluated in triplicate using [3H]-thymidine
uptake (in counts per minute; CPM). Data are from one experiment representative of 3
experiments. In all panels, data are expressed as Mean ± SEM and the p values were
calculated using unpaired two-sided Student’s t-test. *p<0.05; **p<0.01; ***p<0.001;
****p<0.0001. ns, not significant.
Mechanism of regulation of MDSC function by IFNAR1. We next sought to
delineate putative mechanisms by which downregulation of the IFNAR1 provides a
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license for immune suppressive activities of MDSC. To this end, WT and SA EL4 TB
mice were treated with CD8 antibody to eliminate differences in tumor growth, PMNMDSC were collected 18 days after tumor inoculation and expression of genes implicated
in MDSC suppressive activity was evaluated. We found that PMN-MDSC from SA TB
mice had markedly lower expression of Arg1 and downregulation of Ptgs2, and Nox2
(Fig. 3.4A). As we described previously, ROS production is one of the hallmarks of
PMN-MDSC activity; and NOX2 is directly involved in production of ROS by PMNMDSC. Because of substantial decrease in Nox2 expression, we assessed the level of
ROS in PMN-MDSC. Both spleen and tumor PMN-MDSC from SA TB mice
demonstrated markedly lower level of ROS than WT mice (Fig. 3.4B). These results
suggest that down-regulation of IFNAR1 on MDSC is required for their ability to express
several critical mediators of the immune suppressive activity.
To gain further insight into the mechanisms delineating the effects of IFN1 on
suppressive activities, we performed RNA sequencing of PMN-MDSC from WT and SA
EL4 TB mice. Most prominent differences in the expression of specific transcripts are
shown in Fig. 3.4C. Pathway analysis revealed that stabilization of IFNAR1 in PMNMDSC in TB mice resulted in significant inhibition of glycolysis in these cells, as well as
several pathways associated with cells movement and chemokine signaling (Fig. 3.4D).
Thus, unabated IFNAR1 signaling was associated with marked reduction of several major
mediators of PMN-MDSC suppressive activity.
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Figure 3.4. Effect of Ifnar1SA on mRNA expression gene expression by PMNMDSCs. (A) mRNA expression of genes associated with immunosuppressive activity in
PMN-MDSCs. Analyzed by RT-qPCR. (B) Reactive oxygen species (ROS) levels by
PMN-MDSCs from spleen and tumors of WT and Ifnar1SA tumor-bearing mice (n=4).
(C) Expression heatmap of significantly affected genes (FDR<5%) for different fold
change thresholds. (D) List of canonical pathways downregulated that were determined
by Ingenuity Pathway Analysis (IPA) as significantly enriched pathways affected by
Ifnar1SA. N = number of genes; p value = enrichment; FDR = false discovery rate of
significantly genes (FDR<10%) for different fold change thresholds; Z = activation zscores calculated by IPA represent predicted canonical pathway decreasing (Z threshold
of 2 is used to call the state). Panel of top genes affected by Ifnar1SA for each pathway.
Data are expressed as Mean ± SEM and the p values were calculated using unpaired twosided Student’s t-test.
*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001, ns, not
significant.
Mechanisms regulating IFNAR1 expression in MDSC. We next sought to
identify the mechanisms regulating IFNAR1 expression on MDSC. It is known that
IFNAR1 level is regulated by phosphorylation-dependent ubiquitination and degradation
of the IFNAR1 chain

186

. This proteolytic inactivation of IFNAR1 is mediated by either
204

protein kinase D2 in response to IFN1 itself

or by p38 protein kinase in response to

the non-ligand stimuli that are present in tumor microenvironment including pro49

inflammatory cytokines, tumor-derived vesicles, and the deficit of oxygen/nutrients
leading to the integrated stress response

182,186,187

. Therefore, we tested the effect of

tumor-derived factors on IFNAR1 expression by exposing mouse PMN or Mon to the
tumor explant supernatant (TES) obtained from different EL-4 tumors. We observed
marked down-regulation of IFNAR1 in PMN and Mon treated with TES (Fig. 3.5A),
which contained negligible (if any) amounts of IFNα and IFNβ (Fig. 3.5B) suggesting the
role of non-ligand factors in decrease in IFNAR1 levels. Similar experiments were
performed with PMN isolated from healthy donors. TES from different primary human
tumors, as well as supernatant from tumor cell line PCI-30, caused substantial decreases
in IFNAR1 expression (Fig. 3.5C). TES also caused significant downregulation of
IFNAR1 in PMN, but not Mon generated from CD34+ progenitor cells (Fig. 3.5D).
Thus, tumor-derived factors present in TES from both mouse and human tumor
cells caused downregulation of the receptor. This may explain the decrease of IFNAR1 in
PMN-MDSC from peripheral lymphoid organs. However, since down-regulation of
IFNAR1 was markedly stronger in tumors than in spleens, we asked whether anything
could further downregulate IFNAR1 in MDSC in the tumor site. Hypoxic conditions
downregulated IFNAR1 in melanoma cells
IFNAR1 expression

182

186

and hypoxic areas of solid tumors lacked

. Exposure of mouse PMN to hypoxia or lactic acid (major

contributors to endoplasmic reticulum (ER) stress response) notably decreased the
receptor levels (Fig. 3.5E). We and others previously implicated ER stress in immune
suppressive activity of MDSC

81,83

. Therefore, we explored the role of ER stress in

regulation of IFNAR1 in MDSC. ER stress inducer thapsigargin (THG) caused marked
reduction in IFNAR1 expression in mouse PMN and Mon (Fig. 3.5F). As observed in
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murine cells, in vitro treatment of human PMN with THG also resulted in dramatic
downregulation of IFNAR1 (Fig. 3.5G). Therefore, we asked whether pre-treatment of
PMN with IFNβ prevents the acquisition of suppressive activity. Indeed, IFNβ abrogated
the suppressive functions of THG-induced PMNs (Fig. 3.5H). Thus, it appears that the
ER stress inducible suppressive activity of MDSC could be abrogated by IFN1.

Figure 3.5. Tumor microenvironment induces downregulation of IFNAR1 in
MDSCs. (A) IFNAR1 levels on bone marrow PMN (left) or Mon (right) treated for 18h
with 20% TES in vitro. (n=2-4). (B) IFNβ and IFNα amount in 8 different types of TES
measured by ELISA. (C) Expression of IFNAR1 on PMNs, isolated from healthy donors’
blood (n=3), treated for 16-18 h with 6 different TES (30%) and 30% PCI-30 tumorconditioned media (TCM) in vitro. (D) IFNAR1 levels on CD34-derived PMNs or Mon
treated with 30% TES at day 7 followed by flow cytometry analysis on day 8 (n=6). (E)
BM PMNs (n=3) were cultured in 0.5% O2 (hypoxia) or 20uM lactic acid for 16-18h
before measuring IFNAR1 levels by flow cytometry. (F) IFNAR1 levels on BM PMNs or
Mon treated for 16-18h with different doses of ER stress inducer thapsigargin (THG;
2uM, 1uM or 0.5uM) in vitro (n=3). (G) Expression of IFNAR1 PMNs from healthy
donors treated for 16-18h with 1uM THG. (H) PMNs isolated from healthy donors’ blood
were pretreated with 1000U IFNβ for 2h followed by incubation with 1µM THG for 1820h. PMNs were extensively washed, and then used in CD3/CD28-induced T cell
proliferation assay (n=4). Data are expressed as Mean ± SEM and the p values were
calculated using unpaired two-sided Student’s t-test. *p<0.05; **p<0.01; ***p<0.001,
ns, not significant.
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We focused on the mechanisms underlying IFNAR1 downregulation in MDSC.
Since p38 was implicated in the ligand-independent IFNAR1 ubiquitination and
degradation

182,186,187

, we investigated the role of this kinase. Deletion of p38 completely

prevented downregulation of IFNAR1 in spleen PMN-MDSC (Fig. 3.6A) suggesting an
important role of p38 kinase in regulation of IFNAR1 on MDSC.
Treatment of mouse PMN with TES caused up-regulation of phospho-p38 in
PMN without affecting the total amount of this protein (Fig. 3.6B). Tumor PMN-MDSC
had higher levels of phospho-p38 than spleen PMN-MDSC (Fig. 3.6C). As expected,
hypoxia increased phospho-p38 in PMN (Fig. 3.6D). In the absence of p38 (in p38 KO
mice), expression of IFNAR1 was dramatically higher in PMN treated with TES alone or
in combination with hypoxia (Fig. 3.6E). Treatment of human PMN with TES that
caused downregulation of IFNAR1 (Fig. 3.5C) induced up-regulation of phospho-p38
(Fig. 3.6F). These data collectively suggest that activation of p38 kinase by TES or
hypoxia mediates down-regulation of IFNAR1 on MDSC.

Figure 3.6. Downregulation of IFNAR1 in MDSCs is mediated by p38. (A) IFNAR1
levels on PMN-MDSCs from tumor-free or WT and p38 KO (Mapk14-/-) TB mice. Each
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dot represents an individual mouse (n=3). (B) Phosphorylation and total p38 protein in
BM PMNs treated with 20% TES for 18h in vitro. (C) Histogram (left) of
phosphorylation of p38 (p-p38) in spleen (red) and tumor (blue) PMN-MDSCs compared
to isotype (gray). Each dot represents an individual mouse (n=4; right). (D) BM PMNs
were cultured in 0.5% O2 for 2h and p-p38 was measured by flow cytometry (n=2). (E)
IFNAR1 levels on BM PMNs from WT or p38 KO cultured with 30% TES in normoxia
or hypoxia for 16-18h (n=3). (F) Phosphorylated and total p38 protein in HD PMNs
treated with different TES (30%) or THG (1µM) for 16-18h in vitro. Data are expressed
as Mean ± SEM and the p values were calculated using unpaired two-sided Student’s ttest. *p<0.05; **p<0.01; ***p<0.001, ns, not significant.
Therapeutic regulation of p38 abrogated suppressive activity of MDSC and
elicits the antitumor effects. These results suggest that inhibition of p38 kinase may
prevent down-regulation of IFNAR1 expression and ensuing acquisition of suppressive
activities by MDSC. To test this possibility, we used the p38 kinase inhibitor LY2228820
(Ralimetinib). In healthy donor PMN, downregulation of IFNAR1 caused by TES was
abrogated by inhibition of p38 kinase activity (Fig. 3.7A). Similar results were obtained
with mouse BM PMN and Mon (Fig. 3.7B). Administration of LY2228820 also inhibited
the suppressive activity of spleen PMN-MDSC from EL4 TB mice (Fig. 3.7C) as well as
of PMN from control mice treated with TES (Fig. 3.7D). In contrast, treatment of control
PMN with LY2228820 alone did not affect their ability to regulate T cell proliferation
(Fig. 3.7E). These combined results suggest that a p38 kinase inhibitor may show
enhanced antitumor effect when combined with an IFN1 inducer. To test this hypothesis,
TB mice were treated with Poly:IC (inducer of IFN1) and LY2228820. Treatment with
Poly:IC alone or p38 inhibitor alone did not have substantial effect on the proportion or
absolute number of myeloid cells, PMN-MDSC, M-MDSC, macrophages, or DCs in
spleen. Combination therapy caused only a modest increase in the number of DCs but
had minimal effect on other myeloid cell populations (Fig. S3.4). Treatment of TB mice
with Poly:IC and LY2228820 alone had very minor effect on tumor growth. However,
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combination of these compounds had substantial antitumor activity (Fig. 3.7F). This
effect was abrogated by treatment with anti-CD8 antibody (Fig. 3.7G). When suppressive
activity of PMN-MDSC was compared in these mice (with the same tumor burden), only
PMN-MDSC from untreated TB mice were able to inhibit T-cell proliferation, whereas
no suppressive activity was observed in PMN-MDSC isolated from treated mice (Fig.
3.7H). Thus, stabilization of IFNAR1 by inhibition of p38 kinase resulted in antitumor
effect in combination with type I interferon induction.

Discussion
In this study we identified the role of IFN1 in restricting the acquisition of immune
suppressive activity by MDSC. Furthermore, our data indicated that tumor derived
factors-driven p38 kinase-dependent downregulation of IFNAR1 represents a
mechanism, by which this role of the IFN1 pathway in myeloid cells is overwhelmed
during tumorigenesis leading to the acquiescence of immune suppressive activities.
Only a proportion of PMN in cancer patients acquires features of MDSC

12

. The

presence of PMN-MDSC and M-MDSC in cancer patients is correlated with a negative
clinical outcome 160. It indicates, that at any given moment, populations of classical PMN
and Mon co-exist with immune suppressive PMN-MDSC and M-MDSC. What would
prevent all PMN and Mon from acquiring characteristics of MDSC? We hypothesized
that there could be a mechanism that restricts acquisition of immune suppressive activity
by PMN and Mon. Our data suggest that whereas the IFNAR1-mediated IFN1 signaling
may be such mechanism, this pathway is inactivated during tumorigenesis.
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Figure 3.7. Effect of pharmacological inhibition of p38 phosphorylation of MDSC
function and tumor growth. (A) Healthy donors PMNs were pre-treated with 1µM
LY2228820 (p38 inhibitor; p38i) followed by 16-18hr incubation with 30% TES.
IFNAR1 levels were measured by flow cytometry (n=3) and expressed as fold changes
over untreated cells. (B) IFNAR1 expression on BM PMNs and Mon pre-treated with
1µM p38i followed by incubation with 20% TES (n=3) and expressed as fold changes
over untreated cells. (C) HPC-derived PMN-MDSCs were treated with 1µM p38i before
assessing their suppressive activity in triplicates. Two experiments with the same results
were performed. (D) Suppressive function of PMN-MDSCs from spleen of EL-4 TB
mice after in vitro treatment for 3h with 1µM p38i before co-culture with responder T
cells. (E) BM PMNs from tumor-free mice were treated with 1µM p38i for 3h prior the
suppression assay. (F) MC38 tumor growth in mice treated with Poly I:C and p38i (n=4).
(G) MC38 tumor growth in mice treated with anti-CD8 antibody, Poly I:C and p38i
(n=5). Control are mice treated with PBS. (H) Suppressive activity of spleen PMNMDSCs from control or anti-CD8 antibody, Poly I:C and p38i treatment group. In all
panels, data are expressed as means ± SEM and the p values were calculated using
unpaired two-sided Student’s t-test. *p<0.05; **p<0.01; ***p<0.001, ns, not significant.
Our recent work demonstrated that IFNAR1 was downregulated on all types of cells
in the tumor microenvironment of colorectal cancers leading to inactivation of the IFN1
pathway and generation of immune privileged niches

181,182

. We found that

downregulation of IFNAR1 on MDSC was not restricted to tumor site, it was observed in
peripheral blood of cancer patients and in spleens of TB mice. However, IFNAR1
55

downregulation was higher in tumor MDSC than in spleen MDSC. It was associated with
more potent suppressive activity of MDSC in tumors than in spleens. This was consistent
with previous observations

31,32,37,205

and suggested that downregulation of IFNAR1 and

suppressive activity of MDSC could be linked. The important role of IFN1 in MDSC
suppressive activity was established directly in two sets of experiments: suppressive
activity of MDSC generated by exposure to tumor-derived factors present in TES and
caused by ER stress inducer thapsigargin. In both experimental systems, IFNβ blocked
the suppressive abilities of MDSCs. Whereas in tumor-free mice, deletion of IFNAR1 did
not suffice to convert PMN or Mon to suppressive MDSC, the latter is facilitated by the
presence of additional positive signals, for instance activation of STAT3, NF-kB or other
mechanism mediated by tumor-derived factors, as described in previous studies

36

.

However, expression of IFNAR1 was required to prevent this conversion and led to
inactivation of tumor suppressive activities. This conclusion is based on the experiments
with Ifnar1S526A (SA) mice that had stable expression of the receptor. MDSC in these
mice lost suppressive activity. These data suggest that downregulation of the receptor is
one of the major mechanisms that regulate the IFN1 pathway in MDSC and enable their
immune suppressive properties.
Our data also suggest a mechanism by which IFN1 regulates the activities of MDSC.
Presented here data show that downregulation of IFNAR1 contributes to expression of
Arg1 and Nox2, two critical mediators of MDSC suppressive activities. Given that these
mediators are expressed downstream of STAT3
suppressed by IFN1

209

21,208

, whose transcriptional activity is

, it is plausible that downregulation of IFNAR1 contributes to

maintaining STAT3 activities and relevant STAT3-driven immune suppression.
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Additional mechanisms hinted by results of transcriptional profiling (Figure 4c-d) also
cannot be ruled out and merit further investigation.
What could cause IFNAR1 downregulation in MDSC? Our data demonstrated that
TES causes decreased IFNAR1 expression in human and mouse PMN and Mon. Since
neither IFNα nor IFNβ were detectable in those TES, ligand independent downregulation
of IFNAR1 was more likely. TES contains multiple cytokines and tumor-derived
extracellular vesicles that can cause pathological MDSC activation

210-212

. In addition,

cells from SA mice were shown to be relatively deficient in uptake of the tumor-derived
extracellular vesicles

185

, which may partially explain lack of suppressive activity.

However, it is unlikely that one or even a few of these mostly redundant factors are solely
responsible for this phenomenon. The common denominator for ER stress and tumor
derived factors promoting downregulation of IFNAR1 is the activation of p38 kinase. We
found that deletion of p38 completely abrogated downregulation of IFNAR1 in MDSC.
Similar results were obtained with selective p38 inhibitor, strongly suggesting that p38
activation may be major mechanism that regulate IFNAR1 expression in MDSC.
Our results suggest that expression of IFNAR1 on MDSC may be a critical
mechanism regulating their suppressive activity. Pharmacological regulation of the
receptor by inhibiting p38 activation substantially enhance antitumor effect of IFN1
inducers and thus may open a new therapeutic opportunity.

Methods
Human Samples. Peripheral blood (PB) was collected from untreated cancer
patients at the Helen F. Graham Cancer Center. The study was approved by the
institutional review boards (IRBs) of the Christiana Care Health System at Helen F.
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Graham Cancer Center and The Wistar Institute. All the patients signed IRB approved
consent forms. PB was collected from i) 12 patients with non-small cell lung cancer and 5
with small cell lung cancer; (ii) 5 patients with breast cancer, (iii) 10 patients with
colorectal cancer, (iv) 4 patients with pancreatic adenocarcinomas, (v) 3 patients with
esophageal cancer; (vi) 3 patients with head and neck cancer, (vii) 1 patient with gastric
cancer, and (viii) 1 patient had renal cancer. In some patients with lung, colorectal, renal
or head and neck cancer, tumor tissues (0.2 - 1g) were surgically removed. Ages of
cancer patients were between 46 and 92 years (median, 70 years). Peripheral sample of
blood from 21 healthy donors with ages 30 to 64 (median, 55 years) were used as control
for cancer patients or for in vitro experiments.
Mice. All experiments with animals were approved by IACUC of The Wistar Institute.
Balb/c or C57BL/6 mice (female, 6–8-week-old) were obtained from Charles River. OT-I
TCR-transgenic mice (C57Bl/6-Tg(TCRaTCRb)1100mjb) (female, 6–8 week old) and
Pmel mice (B6.Cg-Thy1a/Cy Tg(TcraTcrb)8Rest/J) were purchased from Jackson
Laboratory. Littermate C57BL/6 (“WT”), C57BL/6 Ifnar1S526A mice (“SA”), Ifnar1-/- and
Mapk14f/f mice were described previously (32). RET melanoma were obtained from Dr.
Umansky (German Cancer Center, Heidelberg, Germany). KPC mice were obtained from
Dr. Robert Vonderheide (University of Pennsylvania.
Bone marrow chimeras. Mixed bone marrow (BM) chimeric mice were obtained as
described previously (25). Briefly, pooled tibial and femoral BM cells from donor mice were
lysed with ACK buffer. BM cells from SA mice transferred to lethally irradiated

syngeneic (CD45.1+) recipients obtained from Charles River. In control BM from wild-

58

type (WT) mice was transferred to lethally irradiated recipients. 8-10 weeks after BM
reconstitution mice were injected s.c. with 5x105 LLC cells and measured tumor growth.
Cell lines and tumor models. Mouse cell lines: EL4 lymphoma, LLC (Lewis
lung carcinoma), CT-26 colon carcinoma, B16F10 melanoma were purchase from
ATCC. MC38 colon carcinoma (provided by I. Turkova, University of Pittsburgh,
Pittsburgh, PA). MethA (methylcholantrene induced) sarcoma cell line was originally
obtained from Dr. Lloyd J. Old (Cancer Research Institute, New York, NY). MethA
tumor was established i.p. in Balb/c mice and passaged in vivo as an ascitic tumor. LLC
or B16F10 and CT-26 tumor-bearing mice were generated by injecting 5x105 tumor cells
s.c. into C57BL/6 or Balb/c mice, respectively. EL-4 and MethA tumor-bearing mice
were generated by injecting 5x105 tumor cells i.p. into C57BL/6 mice. We harvested cells
from ascites tumors by washing the peritoneum with 10 ml of ice-cold MACS buffer. For
MC38 tumor-bearing mice, we injected 1x106 tumor cells s.c. into C57BL/6 mice.
Human cell lines: PCI-30 (head and neck squamous carcinoma) was obtained from
ATCC.
Isolation of human cells. Human PMNs from healthy donors were isolated with
two methods. 1) PMNs were isolated by centrifugation using double density gradient
Histopaque (Sigma). PBMCs were collected using 1.077 and PMNs were collected using
1.119. 2) Whole blood was enriched for PMNs using MACSxpress Neutrophil Isolation
Kit (Miltenyi) following the protocol provided by the manufacturer.
Flow cytometry. Mouse. Single-cell suspensions of BM, spleen and tumors were
prepared, and red cells were removed using ACK lysing buffer. In other experiments,
cells were culture in vitro before flow cytometry analysis was performed. All antibodies
59

incubations were performed for 15 min at 4°C in dark and all centrifugation was done at
1,500 r.p.m. at 4°C for 5 min. Usually up to 1x106 cells were incubated with Fc-block
(BD Biosciences) for 10 min and surface staining was performed at 4°C for 15 min. Cells
were run on LSRII flow cytometer (BD Biosciences) and data were analyzed by FlowJo
(Tristar). Human. Single-cell suspensions from peripheral blood were incubated with Fcblock (Miltenyi) for 10 min and surface staining was performed at 4°C for 30 min. Cells
analyzed as described above. A list of antibodies used are in a Supplementary Table 1.
Isolation of PMN-MDSCs and M-MDSCs. Single-cell suspensions were
prepared from spleen followed by red blood cell removal using ACK buffer. Single-cell
suspensions from tumor tissues were prepared using Mouse Tumor Dissociation Kit
according to the manufacturer’s recommendation (Miltenyi). For PMN-MDSCs isolation,
cells were labeled with biotinylated anti-Ly6G antibody (Miltenyi Biotec), incubated
with streptavidin-coated microbeads (Miltenyi Biotec) and separated on MACS columns
(Miltenyi Biotec). M-MDSCs were sorted by using either FACS Aria II (BD
Biosciences) and MoFlo Astrios EQ (Beckman Coulter) cell sorters. The antibodies for
M-MDSCs isolation are described in Supplementary Table 1.
Suppression Assay. Mouse. After isolation of Ly6G+ or Ly6C+ cells as described
above, cells were plated in U-bottom 96-well plates (duplicates or triplicates) in complete
RPMI. Cells were co-cultured at various ratios with total splenocytes from Pmel or OT-1
transgenic mice in the presence of cognate peptides: OT-1 (SIINFEKL; 0.05 ng/ml) and
Pmel (EGSRNQDWL; 0.1 μg/ml). After 48 h, cells were incubated with [3H]-thymidine
(PerkinElmer) for 16–18 h. Proliferation was measured by using TopCount NXT
instrument (PerkinElmer). Human. In vitro treated PMNs from healthy donors were
60

plated in U-bottom 96-well plates (triplicates) in complete RPMI. Concurrently, CD3+ T
cells were isolated from PBMCs of the same donor using the EasySep Human T Cell
Enrichment Kit (STEMCELL Technologies). PMNs were co-culture at different ratios
with 105 T cells and 2.5 μl of Human T-Activator CD3/CD28 Dynabeads (Gibco). After
48 h, cells were incubated with [3H]-thymidine as described above.
Generation of TES. Mouse. Tumor explant supernatants (TES) were
prepared from excised non-ulcerated EL4, LLC, MC38, Ret melanoma or KPC pancreas
tumors. A small tumor piece (0.5g) was harvested, minced into pieces <3 mm in diameter
and resuspended in complete RPMI. After 16–18 hours of incubation at 37 °C with 5%
CO2, the cell-free supernatant was collected using 0.22 μm filters (EMD Millipore) and
kept at −80 °C. Human. TES were prepared from surgically removed tumors and a small
tumor piece (0.1 – 0.5g) was processed. After 16–18 hours of incubation at 37 °C with
5% CO2, the cell-free supernatant was collected using 0.22 μm filters (EMD Millipore)
and kept at −80 °C.
ELISA. Mouse interferon alpha (IFN-α) and beta (IFN- β) concentrations in TES
were measured by using Mouse IFN Alpha ELISA Kit (TCM) (PBL Assay Science) and
Mouse IFN-beta ELISA Kit (R&D Systems), according to manufacturer’s instructions.
Western blot analysis. Proteins were extracted from BM or HD PMNs in RIPA
buffer followed by western blot staining with anti-p38 (Santa Cruz Biotech) and antiphospho-p38 (Cell Signaling) followed by anti-rabbit-HRP conjugated secondary
antibodies (Sigma Aldrich).
MDSCs generated in vitro. Mouse. Hematopoietic progenitor cells (HPCs) were
isolated from mouse bone marrow by using Lineage depletion kit (Miltenyi), according to
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manufacturer’s instructions. Cells were seeded at 25000 cell/ml in 24 well plates and
recombinant GM-CSF (20 ng/ml; Invitrogen), 20% v/v TES were added at day 1 and day
3. At day 5, Ly6G positive neutrophils were isolated by using anti-Ly6G biotin
(Miltenyi) and streptavidin beads (Miltenyi), according to manufacturer’s followed by
suppression assay. In addition, total cells were stained and analyzed for flow cytometry.
In other experiments, LY2228820 p38 inhibitor (1 μM; Selleckchem) was added to HPC
culture at day 3. Human. Hematopoietic progenitor cells (HPCs) were isolated from cord
blood using the CD34 MicroBead Kit (Miltenyi), according to manufacturer’s
instructions. Cells were seeded at 5x104 cell/ml in 6 well plates with recombinant G-CSF
(100 ng/ml; PeproTech) and GM-CSF (10 ng/ml; PeproTech). At day 7, 30% v/v TES
were added and the next day flow cytometry analysis was performed.
In vitro treatment. Mouse. Splenic PMN-MDSCs isolated from TB mice were
treated with mouse IFNβ (2000 units/ml; PBL Assay Science) for 2 h before assessing
their suppressive activity. Total BM cells were treated with TES (30% v/v) or
thapsigargin (THG) (0.5, 1, 2 μM; Sigma) and recombinant GM-CSF (10 ng/ml) for 1618 h followed by measurement of cell surface IFNAR1 levels by flow cytometry. BM
PMNs treated with lactic acid (20 μM; Sigma Aldrich) and recombinant GM-CSF (10
ng/ml) for 16-18 h followed by flow cytometry analysis. BM PMNs and Mon pre-treated
with LY2228820 p38 inhibitor (1 μM; Selleckchem) or vehicle (DMSO) for 2 h and then
treated with TES (30% v/v) for additional 2 h. Experiments with hypoxia (0.5% O2) for
16-18 were maintained using hypoxic chamber (BioSpherix). Human. HD PMNs were
isolated as described above and treated with TES (30% v/v), TCM (30% v/v) or THG (1
μM; Sigma) and recombinant GM-CSF (20 ng/ml; PeproTech) for 16-18 h. PMNs were
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pre-treated with human IFNβ (2000 units/ml; PBL Assay Science) for 2 h followed by
THG (1 μM) for another 16-18 h before suppression assay as described previously.
In vivo treatment. Depletion of CD8+T cells. To deplete CD8+T cells, 100 μg
anti-CD8 (Bio-XCell) or control PBS per mouse was delivered by i.p. injection at day -1, 0,
4, 8, 12, 16, 18, 22. MC38 (1×106) cells were injected s.c. into C57BL/6 mice. At day 12,

TB mice were treated by gavage with p38 inhibitor LY2228829 (1 mg/kg; Selleckchem)
prepared in methylcellulose. MC38 TB mice received p38 inhibitor every other day and
gavage with analogous volumes of pure methylcellulose was used as a vehicle control.
Poly I:C (100 μg/ml; Sigma) was injected i.p. every day starting from day 12. In other
experiments, MC38 tumor-bearing mice were treated with 100 μg anti-CD8 followed by
Poly I:C and p38i.
Quantitative real time PCR. Total RNA was extracted using the Quick-RNA
Microprep Kit (Zymo Research) according to manufacturer’s protocol. cDNA was
generated with High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems).
qRT-PCR was performed using Power SYBR Green PCR Master Mix (Applied
Biosystems) in 96-well plates. Plates were read with ABI 7500 Fast Real Time PCR
system (Applied Biosystems). Primers are described in Supplementary Table 2.
RNA-Sequencing. Total RNA was extracted from 1-2 million PMN-MDSC using
the Direct-zol RNA Miniprep (Zymo Research, Irvine, CA). RNA quantity was
determined using the Qubit 2.0 Fluorometer (ThermoFisher Scientific, Waltham, MA)
and the quality was validated using the TapeStation RNA ScreenTape (Agilent, Santa
Clara, CA). 75 ng of DNAse I treated, total RNA was used to prepare library for Illumina
Sequencing using the Quant-Seq 3’mRNA-Seq Library Preparation Kit (Lexogen,
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Vienna, Austria). Library quantity was determined using qPCR (KAPA Biosystem,
Wilmington, MA). Overall library size was determined using the Agilent TapeStation and
the DNA High Sensitivity D5000 ScreenTape (Agilent, Santa Clara, CA). Equimolar
amounts of each sample library were pooled, denatured and High-Output, Single- read,
75bp cycle. Next Generation Sequencing was done on a NextSeq 500 (Illumina, San
Diego, CA).
Microarray data from previous study

90

was tested for differences between PMN

and PMN-MDSCs using t-test and p-values were adjusted for multiple testing by Storey
et. al. procedure 213. A list of 633 genes known to be induced by type I interferon at least
10-fold in mice were derived from interferome.org database. Enrichment of interferon
inducible genes among genes significantly downregulated in PMN-MDSC with
FDR<20% was tested using Fisher Exact Test.
RNA-seq data was aligned using Bowtie2 against hg19 genome and RSEM v1.2.12
software

214

was used to estimate gene-level read counts using Ensemble transcriptome

information. DESeq2

215

was used to estimate significance of differential expression

difference between the two experimental groups.. Gene set enrichment analysis was done
on genes passing nominal p<0.05 significance threshold using QIAGEN's Ingenuity®
Pathway Analysis software (IPA®, QIAGEN Redwood City,www.qiagen.com/ingenuity)
using “Canonical Pathways” options. Only pathways

that passed FDR<10% threshold

and had significantly predicted activation state (|Z-score|>2) were reported.
ROS Production. Reactive oxygen species were measured by using oxidationsensitive dye DCFDA (C6827, Molecular Probes/Invitrogen Life Technologies).
Splenocytes were labeled with surface markers, washed, and incubated at 37°C in the
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serum-free RPMI media in the presence of 3 μM DCFDA. After incubation for 30 min,
the cells were analyzed using ﬂow cytometry.
Statistics. Statistical analysis was performed using a two-tailed Student’s t test or
Mann-Whitney test after the analysis of distribution of variables. Significance was
determined at p <0.05. Tumor size evaluation was performed using Two-way ANOVA
with adjustments for repeated measurements. All calculations were made using GraphPad
Prism 7 software (GraphPad Software Inc.).

Supplementary Data

Supplemental Figure 3.1. List of genes involved in IFN1 signaling in PMN-MDSCs
versus PMNs. (A) Affymetrix microarray analysis of genes involved in type 1 interferon
signaling pathway in mouse PMN-MDSCs and neutrophils. (B) RNAseq analysis of
genes involved in type 1 interferon signaling pathway in human LOX1+ PMN-MDSC and
LOX1− PMN.
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Supplemental Figure 3.2. Gating strategy for mouse and human MDSCs. (A) Gating
strategy for CD15+ cells from whole blood of healthy donors and cancer patients. (B)
Flow cytometry analysis of cancer patient’s PMN-MDSCs versus PMNs based on CD15+
marker from PBMCs and PMNs fractions after histopaque gradient centrifugation (top).
Flow cytometry gating for CD14+ M-MDSCs versus Mon based on HLA-DR expression
(bottom), (C) phenotype of EL-4 tumor-bearing mice spleen and tumor PMN-MDSC
(CD11b+Ly6CloLy6G+) and M-MDSC (CD11b+Ly6ChiLy6G-) compared with tumor-free
mice by flow cytometry.
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Supplemental Figure 3.3. IFNAR1 levels in PMN-MDSCs from WT, IFNAR1 KO
and SA tumor-bearing mice. (A) Histogram (left) and cumulative results (right) of
IFNAR1 expression in Ly6G+ cells (PMN-MDSCs) from spleen of control tumor-free or
WT and IFNAR1 KO tumor-bearing mice. (B). EL-4 tumor growth in WT and IFNAR1
KO C57BL/6 mice. Representative of two experiments (n=3). (C) Histogram (left) and
cumulative results (right) of IFNAR1 expression in Ly6G+ cells (PMN-MDSCs) from
spleen of WT and SA tumor-bearing mice. Results of individual mice and mean ± SEM
are shown. (n=4). P<0.0001 in two tailed Student’s t-test. (D) Expression of Irf7 in PMNMDSC isolated from spleen of WT and SA EL4 TB mice. Results of individual
experiments (n=4) are shown. P values were calculated in unpaired two-sided Student’s ttest.
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Supplemental Figure 3.4. Phenotype of myeloid cells after combination therapy. (A)
Percentage of myeloid cells in spleen of MC38 tumor-bearing mice after control (ctrl),
Poly I:C, p38i or Poly I:C + p38i (n=5). (B) Absolute numbers of myeloid cells in spleen
of MC38 tumor-bearing mice after control (ctrl), Poly I:C, p38i or Poly I:C + p38i (n=5).
Individual results and are shown.
Supplemental Table 3.1. List of reagents

Supplemental Table 3.2. Primers sequence
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CHAPTER FIVE: CONCLUSIONS AND FUTURE DIRECTIONS

Summary and main findings
In recent years, MDSC emerged as critically important mediator that suppress
anti-tumor immune responses

1-5

, and directly involved in tumor progression,

angiogenesis and metastasis 2-5. MDSCs are a heterogeneous population of bone marrowderived immature myeloid cells that accumulates in peripheral lymphoid organs and
tumor tissues, which correlate with a poor prognosis and clinical outcome in cancer
patients 2-9. Although, MDSC phenotype and major immune suppressive mechanisms are
now relatively well defined

9,156

, it is still not clear what factors regulate their function

and what is their relationship with other myeloid cells in cancer.
In these studies, we demonstrated several unique features of MDSCs, that
provided us more insight of their biology, as well as their role in suppressing anti-cancer
immunity and limiting the efficacy of cancer immune therapy. First, we identified LOX-1
as a marker for human PMN-MDSC that was not expressed on non-suppressive
neutrophils in cancer patients. In addition, upregulation of LOX-1 in PMN-MDSCs was
associated with their immune suppressive functions, ER stress and lipid metabolism
(Chapter 2). Thus, these mechanisms provided new insight to the biology of MDSCs that
were confirmed in other studies. Second, we further characterized the “MDSC-like” cells
that are pathologically activated myeloid cells lacking potent suppressive activity but
with an increased in migratory activity at early stages of cancer. These cells described in
our study as PMN-MDSC-like cells (PM-LC), are more migratory than normal
neutrophils or PMN-MDSC. In addition, we demonstrated that migration of PM-LC was
accompanied with an increased in their metabolism and ATP levels, representing the first
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step of neutrophils activation and preceding the features of PMN-MDSCs in cancer
(Chapter 2). Third, we identified type 1 interferon as negative regulators of MDSC and
that IFNAR1 downregulation is a critical mechanism regulating the acquisition of
immune suppressive activity by these cells. Downregulation of IFNAR1 in MDSC was
mediated by p38 activation within the tumor microenvironment. Moreover, the selective
pharmacological inhibition of p38 restored IFNAR1 levels and abrogated the activity of
PMN-MDSCs. In combination with Poly I:C, an IFN1 inducer, we observed a substantial
delayed in tumor progression. Thus, it represents an opportunity for therapeutic
intervention that will improve the effect of cancer immune therapies.
In conclusion, we provided the first description of LOX-1 as marker for human
PMN-MDSC in cancer and the mechanisms linked to its upregulation in these cells. In
addition, we described the migratory mechanisms involved in PM-LC preceding their
acquisition of PMN-MDSCs immune suppressive at early stages of cancer. Moreover, we
reported detailed description of regulation of the immune suppressive activity of MDSC
by type 1 interferon, as well as the role of IFNAR1 expression in dictating the function of
these myeloid cells. Finally, we proposed a new combinatorial approach to improve
cancer immunotherapy.
For an extended discussion on these studies, please refer to the discussion section
of chapter 2 (page 24) and chapter 3 (pages 37).
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Future Directions
Our findings described in chapter 2 and 3 greatly increased our knowledge about
the biology and importance of MDSC in mediating immunosuppression in cancer.
Further, they provided insight into unique features of MDSC in comparison with other
myeloid cells, especially monocytes and neutrophils. However, many questions remain.
Chapter 2 provided important information about interesting mechanisms involved in
MDSC that we could further investigate to increase our understanding of their regulation
by negative regulators, such as IFN1, that we described in Chapter 3. Therefore, I will
describe open questions and possible follow up experiments for our last study.
Does IFNAR1 signaling regulates glycolysis in MDSCs? As described
previously in Chapter 3, we performed RNA sequencing to assessed changes in the
transcriptome of PMN-MDSC from WT and Ifnar1 SA tumor-bearing mice.
Interestingly, pathway analysis revealed that stabilization of IFNAR1 in PMN-MDSC in
tumor-bearing mice resulted in significant inhibition of glycolysis in these cells.
Therefore, the question then arises as to how stabilization of IFNAR1 regulates
glycolysis in MDSC. It would be interesting to verify the effect of IFNAR1 stabilization
on metabolic activity of MDSC and take advantage of the techniques used in Chapter 2,
such as seahorse assay, to assess oxidative phosphorylation and glycolysis in these cells.
In addition, other experiment could include measuring glucose uptake and determine
whether there are changes in the expression of glucose transporters and glycolytic
enzymes.
Does IFNAR1 signaling regulates lipid metabolism in MDSCs?

As we

described in Chapter 2, tumor infiltrating MDSCs used mainly fatty acid oxidation
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(FAO). Tumor infiltrating MDSCs have an increased in fatty acid uptake and an
upregulation of FAO enzymes 205,216. In addition, our lab has recently identified fatty acid
transport protein 2 (FATP2) as key transporter for the uptake of fatty acids by MDSCs
216. Moreover, FATP2 is directly involved in the acquisition of immune suppressive
activity by MDSCs and has been suggested as target to selectively inhibit the function of
these myeloid cells in cancer. Interestingly, RNAseq data analyzed in that study, showed
an increase in IFN1 signaling in FATP2 KO MDSCs compared to WT. This suggest a
potential link in lipid metabolism and IFN1 signaling that has not been described yet.
Therefore, it would be interesting to determine if there are changes in FATP2 expression
or fatty acid uptake in WT, IFNAR1 KO and SA MDSCs. Also, measure IFNAR1
expression in FATP2 KO MDSCs. Results from this study could lead to new mechanisms
and a new combinatorial approach treat cancer where. Therefore, is worth exploring.
Is MDSC migration regulated by IFNAR1 signaling? Our data analysis from
RNA sequencing also revealed that MDSC from Ifnar1 SA tumor-bearing mice had a
significant inhibition of pathways associated with cells movement and chemokine
signaling. Recent studies suggested that IFN1 signaling regulates myeloid cell migration
during viral infections 217,218, but in cancer is unclear. To determine whether stabilization
of IFNAR1 regulates the ability of MDSC to migrate spontaneously or in response to
stimuli, experiments using Transwell membrane assay as described in Chapter 2 could be
a great way to answer this question. Also, measuring two main chemokine receptors,
CXCR1 and CXCR2, expressed by MDSCs. Recently, it has been suggested that
interferon regulatory factor 2 (IRF2) could repress MDSCs migration and infiltration 218.
Therefore, it would be very interesting to further explore this mechanism.
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How IFN1 regulates immune suppressive mediators by MDSC? Our data
suggested that a mechanism by which IFN1 regulates MDSC function, was by
dampening the expression of genes implicated in the immune suppressive activity of
these cells. Briefly, we found that PMN-MDSC from SA TB mice had markedly lower
expression of Arg1 and downregulation of Ptgs2, and Nox2. Therefore, we were
wondering how IFN1 regulates the transcription of these major immune mediators of
PMN-MDSC activity. We observed that stabilization of IFNAR1 in PMN-MDSCs
induces an increase in IFN1 signaling based on Irf7 expression. However, RNAseq data
presented in our supplementary data from Chapter 3 has shown that LOX-1+ PMNMDSCs have a downregulation of several interferon regulatory factors (IRFs) besides
Irf7. Therefore, is possible that these transcription factors may repress directly the
expression of these immune suppressive genes in MDSC. To answer this question, it
would be good to first determine if Arg1, Ptgs2, and Nox2 have a binding site for the
different IRFs using http://jaspar.genereg.net. Once this binding site is confirmed, follow
up experiments with chromatin immune precipitation (ChiP) assay as described
previously should be done

216

. In addition, it would be interesting to determine whether

IFN1 signaling can inhibit other mechanism of immune suppression by MDSCs
described in Chapter 1.
Does IFN1 mediate inhibition of IL-8 signaling in MDSC? Another pathway
downregulated in MDSC from IFNAR1 SA tumor-bearing mice was the chemokine
CXCL8 (IL-8) signaling. IL-8 has been linked to the recruitment and activation of
myeloid cells, including MDSCs in the tumor microenvironment, and its serum
concentrations are predictive of responses to cancer therapy
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220-223

. Other studies had

shown that neutralization of IL-8 decreases MDSC and a successful Phase 1 trial has
suggested this as immune therapy approach for cancer224-225. Interestingly, previous
studies have determined that IFN-β is capable of inhibiting IL-8 expression in a variety of
cell types226-227. However, it is not clear if IFN1 can bind to IL-8 promoter and inhibit its
expression or chemo-attractive functions in MDSCs. Therefore, performing ChiP and
Transwell assays could answer these questions. Nevertheless, it will be interesting to
explore the therapeutic effect of IL-8 monoclonal antibody with our combinatorial
therapy approach.
How MDSCs differ from their myeloid counterparts on a cellular and
molecular level in IFNAR1 SA mice? As we described throughout our studies, MDSCs
are a heterogenous population of myeloid cells that arises in pathological conditions

1-3

.

Therefore, is important to determine the specific subset of MDSCs or any novel
population with immune suppressive functions that is negatively regulated by IFN1s. To
answer this question, experiments using mass cytometry and single-cell RNA sequencing
could demonstrate that the complementary use of these two techniques will provide indepth knowledge on the heterogeneity of MDSCs in mice and humans. Recently, several
groups have implemented these techniques to identify MDSC-specific gene expression
signatures or surfaces markers in various types of cancer228-229. Therefore, these state-ofthe-art technologies will increase our knowledge of MDSC heterogeneity and identify
new markers or negative regulators that we could exploit in the future.
Correlation of IFNAR1 expression on MDSCs with cancer patient outcomes.
In our study, we observed downregulation of IFNAR1 in MDSCs from peripheral blood
of cancer patients compared to their counterparts in healthy donors or within the same
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patient. Although we used different types of cancer patient samples, it will be interesting
to evaluate the correlation of IFNAR1 expression in MDSCs with disease outcome. A
recent study demonstrated that IFNAR1 correlated with the outcome of colorectal
patients, however this was based on receptor levels in tumor tissues from a small cohort
of patients. Since we observed changes in IFNAR1 expression in MDSCs from peripheral
blood, we would like to further investigate this receptor levels in patients’ tumors using
immunofluorescence staining described in Chapter 2 and determine changes of IFNAR1
expression in LOX-1+ MDSCs.
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